



# NCDR<sup>®</sup>

NATIONAL CARDIOVASCULAR DATA REGISTRY

## Published Manuscripts Based on NCDR Registries

## Published Registry Manuscripts Table of Contents (TOC)

Legend.....	3
ACTION Registry® .....	4
PUBLISHED.....	4
IN PRESS.....	12
CathPCI Registry® .....	13
PUBLISHED.....	13
IN PRESS.....	29
ICD Registry™ .....	29
PUBLISHED.....	29
IN PRESS.....	37
CARE Registry® .....	38
PUBLISHED.....	38
IN PRESS.....	39
IMPACT Registry® .....	40
<b>PUBLISHED</b> .....	40
IN PRESS .....	40
PINNACLE Registry® .....	41
PUBLISHED.....	41
IN PRESS.....	43
TVT Registry .....	44
PUBLISHED.....	44
IN PRESS .....	45
NCDR-wide Publications.....	46
PUBLISHED.....	46
IN PRESS.....	46

# NCDR<sup>®</sup> Registry Manuscripts

## Legend

### **Manuscript Status is designated as follows:**

- **Published/Full Citation Provided:** Manuscript is in print.
- **In Press:** Manuscript accepted for publication but has not yet appeared in print or on-line.

### **Abbreviations:**

- **Am J Cardiol:** American Journal of Cardiology
- **Am Heart J:** American Heart Journal
- **Br Med J:** British Medical Journal
- **Catheter Cardiovasc Interv:** Catheterization and Cardiovascular Interventions.
- **Circulation:** Circulation
- **Circ: Interv:** Circulation: Cardiovascular Interventions
- **Circulation: Cardiovasc Qual Outcomes:** Circulation: Cardiovascular Quality and Outcomes
- **Clin Med Res:** Clinical Medicine and Research
- **Heart Rhythm:** Heart Rhythm
- **J Am Coll Cardiol:** Journal of the American College of Cardiology
- **JACC Cardiovasc Interv:** Journal of the American College of Cardiology: Cardiovascular Interventions
- **JACC Imaging:** Journal of the American College of Cardiology: Cardiovascular Imaging
- **JAMA:** Journal of the American Medical Association
- **J Cardiovasc Manag:** The Journal of Cardiovascular Management (Pub ended 2005)
- **J Invas Cardiol:** Journal of Invasive Cardiology
- **Journal Biomed Inform:** Journal of Biomedical Informatics
- **J Cardiovasc. Manag:** Journal of Cardiovascular Management
- **NEJM:** New England Journal of Medicine
- **Pharmacoepidemiol Drug Saf:** Pharmacoepidemiology and Drug Safety

**PUBLISHED**

1. **156.** Pandey A, Golwala H, Hall HM, et al; Association of US Centers for Medicare and Medicaid Services Hospital 30-day Risk-Standardized Readmission Metric With Care Quality and Outcomes After Acute Myocardial Infarction: Findings From the National Cardiovascular Data Registry/Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With the Guidelines; JAMA Cardiology; 2017/4/26
2. **104A/53** Miller AL, Simon D, Roe MT, et al; Comparison of Delay Times from Symptom Onset to Medical Contact in Blacks Versus Whites With Acute Myocardial Infarction; AJC; April 15, 2017Volume 119, Issue 8, Pages 1127–1134
3. **97B.** Pokorney SD, Miller AL, Chen AY, et al; Reassessment of Cardiac Function and Implantable Cardioverter-Defibrillator Use Among Medicare Patients With Low Ejection Fraction After Myocardial Infarction; CIRC;2017;135:38–47.
4. **123.** Roswell, RO; Kunkes, J; Chen AY; et al; Impact of Sex and Contact-to-Device Time on Clinical Outcomes in Acute ST-Segment Elevation Myocardial Infarction—Findings From the National Cardiovascular Data Registry; 2017; 6:e004521
5. **137.** Fanaroff AC, Peterson ED, Chen AY, et al. Intensive Care Unit Utilization and Mortality Among Medicare Patients Hospitalized With Non-ST-Segment Elevation Myocardial Infarction; JAMA Cardiology; 1/1/2017;2(1):36-44.
6. **144.** Doll, JA, Hellkamp, AS, Goyal, A; Treatment, Outcomes, and Adherence to Medication Regimens Among Dual Medicare-Medicaid–Eligible Adults With Myocardial Infarction; JAMA Cardiology; 2016;1(7):787-794
7. **129A/64.** Harrison, RW, Simon, D, Miller, AL, et al, Association of hospital myocardial infarction volume with adherence to American College of Cardiology/American Heart Association performance measures: Insights from the National Cardiovascular Data Registry; American Heart Journal; 2016; 178: 95-101
8. **85.** Pandey, A, McGuire, DK, de Lemos, JA, et al; Revascularization Trends in Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease Presenting With Non-ST Elevation Myocardial Infarction: Insights From the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry-Get with the Guidelines (NCDR ACTION Registry-GWTG); Circulation: Cardiovascular Quality and Outcomes. 2016; 9: 197-205
9. **59.** Anstey, DE, Li, S, Thomas, L, et al; Race and Sex Differences in Management and Outcomes of Patients After ST-Elevation and Non-ST-Elevation Myocardial Infarct: Results From the NCDR; Clinical Cardiology; 7/282016
10. **166.** McNamara RL, Kennedy, KF, Cohen, DJ, et al; Predicting In-Hospital Mortality in Patients With Acute Myocardial Infarction; JACC; 2016; Vol. 68; No. 6

11. **127.** Fordyce, CB, Wang, TY, Chen, AY, et al; Long-Term Post-Discharge Risks in Older Survivors of Myocardial Infarction With and Without Out-of-Hospital Cardiac Arrest; JACC; 2016; Vol. 67; No. 17
12. **94.** Hess CN, Hellkamp AS, Roe MT, et al. Outcomes According to Cardiac Catheterization Referral and Clopidogrel Use Among Medicare Patients With Non–ST-Segment Elevation Myocardial Infarction Discharged Without In-hospital Revascularization. J Am Heart Assoc. 2016;5
13. **111.** Faridi KF, Peterson ED, McCoy LA, et al. Timing of First Postdischarge Follow-up and Medication Adherence After Acute Myocardial Infarction. JAMA Cardiol. Published online March 23, 2016.
14. **96.** Vora AN, Peterson ED, Hellkamp AS, et al. Care Transitions After Acute Myocardial Infarction for Transferred-In Versus Direct-Arrival Patients. Circ Cardiovasc Qual Outcomes 9 (1) 2016
15. **82.** Shah RU, de Lemos JA, Wang TY, et al. Post-Hospital Outcomes of Patients With Acute Myocardial Infarction With Cardiogenic Shock Findings From the NCDR. JACC 6 7(7). 2016
16. **171A/C.** Wang TY, Vora AN, Peng SA, et al. Effectiveness and Safety of Aldosterone Antagonist Therapy Use Among Older Patients With Reduced Ejection Fraction After Acute Myocardial Infarction. J Am Heart Assoc. 2016 Jan 21;5(1).
17. **203A.** Pokorney SD, Miller AL, Chen AY, et al. Implantable Cardioverter-Defibrillator Use Among Medicare Patients With Low Ejection Fraction After Acute Myocardial Infarction. JAMA. 2015;313(24):2433-2440. doi:10.1001/jama.2015.6409
18. **172A/C.** Doll JA, Hellkamp A, Thomas L, et al. Effectiveness of cardiac rehabilitation among older patients after acute myocardial infarction. Am Heart J 2015; 170(5): 855-864
19. **172A.** Doll JA, Hellkamp A, Ho PM, et al. Participation in Cardiac Rehabilitation Programs Among Older Patients After Acute Myocardial Infarction. August 3, 2015. JAMA Int Med. doi:10.1001/jamainternmed.2015.3819
20. **183A.** Gruberg L, Hellkamp AS, Thomas LE, et al. The Association of Previous Revascularization With In-Hospital Outcomes in Acute Myocardial Infarction Patients: Results From the National Cardiovascular Data Registry. JACC: Cardiovascular Interventions, Volume 8, Issue 15, 28 December 2015, Pages 1954-1962.
21. **202A.** Goyal A, de Lemos JA, Peng SA., et al. Association of Patient Enrollment in Medicare Part D With Outcomes After Acute Myocardial Infarction. Circ Cardiovasc Qual Outcomes. 2015;8
22. **198A.** Dasari TW, Hamilton S, Chen AY, et al. Non-eligibility for reperfusion therapy in patients presenting with ST-segment elevation myocardial infarction: Contemporary insights from the National Cardiovascular Data Registry (NCDR). Am Heart J 2016;172:1-8.
23. **176A.** Paixao A, Enriquez JR77, Wang TY, et al. Risk Factor Burden and Control at the Time of Admission in Patients with Acute Myocardial Infarction: Results from the NCDR. Am Heart J 2015; 170(1):173-179
24. **173A.** Hess CN, Peterson ED, Peng SA, et al. Use and Outcomes of Triple Therapy Among Older Patients With Acute Myocardial Infarction and Atrial Fibrillation. JACC, 2015; 66:616–27.
25. **203A.** Pokorney SD, Miller AL, Chen AY, et al. Implantable Cardioverter-Defibrillator Use Among

- Medicare Patients With Low Ejection Fraction After Acute Myocardial Infarction. *JAMA*. 2015;313(24):2433-2440. doi:10.1001/jama.2015.6409.
26. **114A.** Kontos MC, Scirica BM, Chen AY, et al. Cardiac arrest and clinical characteristics, treatments and outcomes among patients hospitalized with ST-elevation myocardial infarction in contemporary practice: A report from the National Cardiovascular Data Registry. *Am Heart J* 2015;169:515-522.e
  27. **176A.** Paixao A. Risk Factor Burden and Control at the Time of Admission in Patients with Acute Myocardial Infarction: Results from the National Cardiovascular Data Registry. *AHJ*, Volume 170, Issue 1, Pages 173–179.e1.
  28. **115A.** Kontos MC, Rennyson SL, Chen AY, et al. The association of myocardial infarction process of care measures and in-hospital mortality: A report from the NCDR®. *Am Heart J* 2014;0:1-10.
  29. **147A.** Karowni W, Wang TY, Chen AY, et al. Chronic vitamin K antagonist therapy and bleeding risk in ST elevation myocardial infarction patients. *Heart*. 2014 Oct 21. pii: heartjnl-2014-305931. doi: 10.1136/heartjnl-2014-305931. [Epub ahead of print].
  30. **123A.** Rousan TA, Pappy RM, Chen, AY, et al. Impact of diabetes mellitus on clinical characteristics, management, and in-hospital outcomes in patients with acute myocardial infarction (from the NCDR). *AJC*. 2014 Oct 15;114(8):1136-1144.
  31. **160A.** Bagai A, Wang Y, Wang TY, et al. In-Hospital Switching Between Clopidogrel and Prasugrel Among Patients With Acute Myocardial Infarction Treated With Percutaneous Coronary Intervention: Insights Into Contemporary Practice From the National Cardiovascular Data Registry. *Circ Cardiovasc Interv*. 2014;7:577-584.
  32. **130A.** Hall HM, de Lemos JA, Enriquez JR, et al. Contemporary Patterns of Discharge Aspirin Dosing After Acute Myocardial Infarction in the United States: Results From the National Cardiovascular Data Registry (NCDR). *Circ Cardiovasc Qual Outcomes*. Originally published August 12, 2014.
  33. **110A.** Udell JA, Wang TY, Li S., et al. Clinical Trial Participation After Myocardial Infarction in a National Cardiovascular Data Registry. *JAMA*, August 27, 2014; Volume 312, Number 8, 841-843.
  34. **132A.** Rao KK, Enriquez JR, de Lemos JA, et al. Use of aldosterone antagonists at discharge after myocardial infarction: Results from the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network (ACTION) Registry—Get with the Guidelines (GWTG). *American Heart Journal*, In Press, Corrected Proof, Available online 21 August 2013
  35. **029A.** Wang TY, Magid DJ, Ting HH, et al. The quality of antiplatelet and anticoagulant medication administration among ST-segment elevation myocardial infarction patients transferred for primary percutaneous coronary intervention. *Am Heart J* 2014;0:1-7. *American Heart Journal* - June 2014 (Vol. 167, Issue 6, Pages 833-839, DOI: 10.1016/j.ahj.2014.03.002
  36. **144A.** Beatty AL, Li S, Thomas, L, et al. Trends in Referral to Cardiac Rehabilitation After Myocardial Infarction: Data From the National Cardiovascular Data Registry 2007 to 2012 *J Am Coll Cardiol*. 2014;63(23):2582 doi:10.1016/j.jacc.2014.03.030. In print, 2014 Jun 17;63(23):2582-3. doi: 10.1016/j.jacc.2014.03.030. [Epub 2014 Apr 23]
  37. **074A.** R.L. McNamara, S.C. Chung, T. Jernberg. International Comparisons of the Management of Patients with Non-ST Segment Elevation Acute Myocardial Infarction in the United Kingdom, Sweden, and the United States: The MINAP/NICOR, SWEDEHEART/RIKS-HIA, and ACTION Registry-GWTG/NCDR Registries. *International Journal of Cardiology*, Available online 9 May 2014
  38. **134A.** Lan Shen, Bimal R. Shah, Aro Nam, et al. Implications of prior myocardial infarction for patients presenting with an acute myocardial infarction, *American Heart Journal*, Volume 167, Issue 6, June 2014, Pages 840-845, doi:10.1016/j.ahj.2014.03.009.
  39. **085A.** Xian Y, Chen AY, Thomas L, et al. Sources of Hospital-Level Variation in Major Bleeding Among Patients With Non-ST-Segment Elevation Myocardial Infarction: A Report From the National

- Cardiovascular Data Registry (NCDR). *Circ Cardiovasc Qual Outcomes*. 2014 Mar 1;7(2):236-43. doi: 10.1161/CIRCOUTCOMES.113.000715.[Epub 2014 Mar 4]
40. **151A.** Mumma Bryn E., Kontos Michael C., Peng S. Andrew, Diercks Deborah B., Association Between Prehospital ECG Use and Patient Home Distance from the PCI Center on Total Reperfusion Time in STEMI Patients: A Retrospective Analysis from the NCDR , *American Heart Journal* (2014), doi: 10.1016/j.ahj.2014.03.014
  41. **065A.** Sherwood MW, Wiviott SW, Peng SA, et al. Early Clopidogrel Versus Prasugrel Use Among Contemporary STEMI and NSTEMI Patients in the US: Insights From the National Cardiovascular Data Registry. *J Am Heart Assoc*. 2014; 3: e000849. Originally published April 14, 2014. doi:10.1161/JAHA.114.000849
  42. **050A.** Gupta N, Washam JB, Mountantonakis SE, et al. Characteristics, Management, and Outcomes of Cocaine-Positive Patients With Acute Coronary Syndrome (from the National Cardiovascular Data Registry). *The American Journal of Cardiology*, Volume 113, Issue 5, 1 March 2014, Pages 749-756.
  43. **139A.** Harskamp RE, Wang TY, Bhatt DL, et al. Hospital patterns of medical management strategy use for patients with non-ST-elevation myocardial infarction and 3-vessel or left main coronary artery disease. *Am Heart J*. 2014 Mar;167(3):355-362.e3.
  44. **145A.** Waldo WS, Brenner DA, Li S, et al. Reperfusion times and in-hospital outcomes among patients with an isolated posterior myocardial infarction: Insights from the National Cardiovascular Data Registry (NCDR). *Am Heart J* 2014;167:350-4.
  45. **120A.** Patel JH, Gupta R, Roe MT, et al. Influence of Presenting Electrocardiographic Findings on the Treatment and Outcomes of Patients with Non-ST-Elevation Myocardial Infarction. *Am J Cardiol*. Volume 113, Issue 2, 15 January 2014, Pages 256–261
  46. **119A.** Anderson ML, Peterson ED, Peng AS, et al. Differences in the Profile, Treatment, and Prognosis of Patients With Cardiogenic Shock by Myocardial Infarction Classification: A Report From National Cardiovascular Drug Registry. *Circ Cardiovasc Qual Outcomes*. 2013; 6, 708-715. Published online before print; November 12, 2013. Doi:10.1161/CIRCOUTCOMES.113.000262
  47. **028A.** Desai NB, Peterson ED, Chen AY, et al. Balancing the risk of mortality and major bleeding in the treatment of NSTEMI patients – A report from the National Cardiovascular Data Registry Original Research Article *American Heart Journal*, Available online 11 October 2013., In Print: Volume 166, Issue 6, December 2013, Pages 1043-1049.e1, doi:10.1016/j.ahj.2013.09.004.
  48. **73A.** Peacock WF, Kontos MC, Amsterdam E, et al. Impact of Society of Cardiovascular Patient Care Accreditation on Quality: An Action Registry®-Get With the Guidelines™ Analysis. *Crit Pathw Cardiol*. 2013 Sep;12(3):116-120.
  49. **132A.** Rao KK, Enriquez JR, de Lemos JA, et al. Use of aldosterone antagonists at discharge after myocardial infarction: Results from the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network (ACTION) Registry–Get with the Guidelines (GWTG). *American Heart Journal*, In Press, Corrected Proof, Available online 21 August 2013

50. **101A.** Acharjee S, Roe MT, Amsterdam EA, et al. Relation of Admission High-Density Lipoprotein Cholesterol Level and In-Hospital Mortality in Patients With Acute Non-ST Segment Elevation Myocardial Infarction (from the National Cardiovascular Data Registry). *The American Journal of Cardiology*, In Press, Corrected Proof, Available online 25 July 2013 . In print, Volume 112, Issue 8, 15 October 2013, Pages 1057-1062, doi:10.1016/j.amjcard.2013.05.050.
51. **90A.** Diercks BD, Kontos, MC, Hollander JE, et al. ED administration of thienopyridines in non-ST-segment elevation myocardial infarction: Results from the NCDR. *Am J Emerg Med* (2013); 31(7): 1005-1011
52. **025A.** Scirica BM, Kadakia MB, de Lemos JA, et al. Association between Natriuretic Peptides and Mortality among Patients Admitted with Myocardial Infarction: A Report from the ACTION Registry(R)-GWTG™. *Clin Chem*. 2013 Apr 29. [Epub ahead of print]
53. **067A.** Hanna EB, Alexander KP, Chen AY, et al. Characteristics and In-Hospital Outcomes of Patients With Non-ST-Segment Elevation Myocardial Infarction Undergoing an Invasive Strategy According to Hemoglobin Levels. *Am J Cardiol*. 2013 Apr 15;111(8):1099-103.
54. **045A.** Mogabgab O, Wiviott SD, Antman EM, et al. Relation Between Time of Symptom Onset of ST-Segment Elevation Myocardial Infarction and Patient Baseline Characteristics: From the National Cardiovascular Data Registry. *Clin Cardiol*. March 2013. doi: 10.1002/clc.12101
55. **100A.** Enriquez JR, de Lemos JA, Parikh SV, et al. Association of chronic lung disease with treatments and outcomes patients with acute myocardial infarction. *Am Heart J*. 2013 Jan;165(1):43-9.
56. **106A.** Riley RF, Newby LK, Don CW, et al. Guidelines-based treatment of anaemic STEMI patients: practice patterns and effects on in-hospital mortality: a retrospective analysis from the NCDR. *European Heart Journal: Acute Cardiovascular Care* (2013) 2(1): 35-43.
57. **062A.** Vavalle JP, Lopes RD, Chen AY, et al. Hospital Length of Stay in Patients with Non-ST-segment Elevation Myocardial Infarction. *Am J Medicine* (2012) 125, 1085-1094.
58. **109A.** Shah RV, Holmes D, Anderson M, et al. Risk of Heart Failure Complication During Hospitalization for Acute Myocardial Infarction in a Contemporary Population Insights From the National Cardiovascular Data ACTION Registry. *Circ Heart Fail*. 2012;5:693-702.
59. **077A.** Miller AL, Dib C, Li L, et al. Left Ventricular Ejection Fraction Assessment Among Patients With Acute Myocardial Infarction and Its Association With Hospital Quality of Care and Evidence-Based Therapy Use. *Circ Cardiovasc Qual Outcomes*. 2012 Sep 1;5(5):662-71.
60. **040A.** Lopes RD, Li L, Granger CB, et al. Atrial Fibrillation and Acute Myocardial Infarction: Antithrombotic Therapy and Outcomes. *Am J Medicine* (2012) 125, 897-905.
61. **066A-B.** Hanna EB, Chen AY, Roe MT, et al. Characteristics and in-hospital outcomes of

patients presenting with non–ST-segment elevation myocardial infarction found to have significant coronary artery disease on coronary angiography and managed medically: Stratification according to renal function. *Am Heart J*. Volume 164, Issue 1, Pages 52-57.e1, July 2012.

62. **031A.** Maddox TM, Ho PM, Tsai TT, et al. Clopidogrel Use and Hospital Quality in Medically Managed Patients With Non-ST-Segment-Elevation Myocardial Infarction. *CIRC Cardiovasc Qual Outcomes*. 2012;5 523-531
63. **060A.** Chin CT, Wang TY, Li S, et al. Comparison of the Prognostic Value of Peak Creatine Kinase-MB and Troponin Levels Among Patients With Acute Myocardial Infarction: A Report from the Acute Coronary Treatment and Intervention Outcomes Network Registry–Get With The Guidelines. *Clin Cardiol*. 2012;35(7):424-9.
64. **059A.** Piña IL, Cohen MG, Rodriguez CJ, et al. Differences in Treatment Patterns and Outcomes Between Hispanics and Infarction: Results From the NCDR ACTION Registry GWTG Non-Hispanic Whites Treated for ST-Segment Elevation Myocardial Infarction. *JACC*. 2012;59; 630-631.
65. **039A.** Subherwal S, Peterson ED, Chen AY, et al. Admission International Normalized Ratio Levels, Early Treatment Strategies, and Major Bleeding Risk Among Non–ST-Segment–Elevation Myocardial Infarction Patients on Home Warfarin Therapy: Insights From the National Cardiovascular Data Registry. *CIRC*. 2012;125 1414-1423.
66. **046A.** Yeo KK, Li S, Amsterdam EA, et al. Comparison of Clinical Characteristics, Treatments and Outcomes of Patients With ST-Elevation Acute Myocardial Infarction With Versus Without New or Presumed New Left Bundle Branch Block (from NCDR®). *Am J Cardio*. 2012; Vol. 109, Issue 4, Pages 497-501.
67. **057A.** Fox CS, Muntner P, Chen AY, et al. Health Services and Outcomes Research Short-Term Outcomes of Acute Myocardial Infarction in Patients With Acute Kidney Injury A Report From the National Cardiovascular Data Registry. *CIRC*. 2012; 125: 497-504.
68. **061A.** Das SR, Alexander KP, Chen AY, et al. Impact of Body Weight and Extreme Obesity on the Presentation, Treatment, and In-Hospital Outcomes of 50,149 Patients With ST-Segment Elevation Myocardial Infarction: Results From the NCDR (National Cardiovascular Data Registry). *JACC*. 2011; 58:2642-2650.
69. **011A.** Melloni C, Roe MT, Chen AY, et al. Use of Early Clopidogrel by Reperfusion Strategy Among Patients Presenting With ST-Segment Elevation Myocardial Infarction. *CIRC: Cardiovasc Qual Outcomes* 2011;4 603-609.
70. **066A-A.** Hanna EB, Chen AY, Roe MT, et al. Characteristics and In-Hospital Outcomes of Patients With Non–ST-Segment Elevation Myocardial Infarction and Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention. *JACC Cardiovasc Interv*. 2011 Sep;4(9):1002-8.
71. **069A.** Wiviott SD, Saucedo JF, Antman EM, et al. Use of Emergency Medical Service Transport Among Patients With ST-Segment–Elevation Myocardial Infarction Findings From the National

72. **038A.** Wang TY, Nallamothu BK, Krumholz HM, et al. Association of Door-In-Door-Out Time with Reperfusion Delays and Outcomes Among Patients Transferred for Primary Percutaneous Coronary Intervention. *JAMA*, 2011; 305(24); 3540-3547.
73. **019A.** Abtahian F, Olenchok B, Ou FS, et al. Effect of prior stroke on the use of evidence- based therapies and in-hospital outcomes in patients with myocardial infarction (from the NCDR ACTION GWTG registry). *Am J Cardiol*. 2011 May 15;107(10):1441-6.
74. **021A.** Kontos MC, Diercks DB, Ho PM, et al. Treatment and outcomes in patients with myocardial infarction treated with acute  $\beta$ -blocker therapy: Results from the American College of Cardiology's NCDR®. *Am Heart J*. 2011;161:864-70.
75. **055A.** Don CW, Roe, MT, Li S, et al. Temporal trends and practice variations in clopidogrel loading doses in patients with non–ST-segment elevation myocardial infarction, from the National Cardiovascular Data Registry. *Am Heart J*, Volume 161, Issue 4, April 2011, Pages 689-697.
76. **068A.** Britton KA, Aggarwal V, Chen AY, et al. No association between hemoglobin A1c and in-hospital mortality in patients with diabetes and acute myocardial infarction. *Am Heart J*. Volume 161, Issue 4, April 2011, Pages 657-663.
77. **071A.** Mathews R, Peterson ED, Chen AY, et al. In-Hospital Major Bleeding During ST-Elevation and Non-ST-Elevation Myocardial Infarction Care: Derivation and Validation of a Model from the ACTION Registry®-GWTG™. *Am J Cardiol*. 2011 Apr 15;107(8):1136-43.
78. **058A.** Chin CT, Chen AY, Wang TY, et al. Risk adjustment for in-hospital mortality of contemporary patients with acute myocardial infarction: the acute coronary treatment and intervention outcomes network (ACTION) registry-get with the guidelines (GWTG) acute myocardial infarction mortality model and risk score. *Am Heart J*. 2011 Jan;161(1):113-122.e2.
79. **084A.** Alexander, KP, Wang TY, Li S, et al. Randomized Trial of Targeted Performance Feedback to Facilitate Quality Improvement in Acute Myocardial Infarction Care. *Circ Cardiovasc Qual Outcomes* 2011;4;129-135.
80. **022A.** Kontos MC, de Lemos JA, Ou FS, et al. Troponin-positive, MB-negative patients with non-ST-elevation myocardial infarction: An undertreated but high-risk patient group: Results from the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network-Get With The Guidelines (NCDR ACTION-GWTG) Registry. *Am Heart J*. 2010 Nov;160(5):819-25.
81. **030A.** Kim MS, Wang TY, Ou FS, et al. Association of prior coronary artery bypass graft surgery with quality of care of patients with non-ST-segment elevation myocardial infarction: a report from the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With the Guidelines. *Am Heart J*. 2010 Nov;160(5):951-7.
82. **036A.** Forman DE, Chen AY, Wiviott SD, et al. Comparison of outcomes in patients aged <75, 75 to 84, and  $\geq$  85 years with ST-elevation myocardial infarction (from the ACTION Registry- GWTG). *Am*

85. **044A-B.** Peterson ED, Roe MT, Chen AY, et al. The NCDR ACTION Registry-GWTG: transforming contemporary acute myocardial infarction clinical care. *Heart*. 2010 Nov;96(22):1798-802.
86. **020A.** Diercks DB, Owen KP, Kontos MC, et al. Gender differences in time to presentation for myocardial infarction before and after a national women's cardiovascular awareness campaign: a temporal analysis from the Can Rapid Risk Stratification of Unstable Angina Patients Suppress ADverse Outcomes with Early Implementation (CRUSADE) and the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network-Get with the Guidelines (NCDR ACTION Registry-GWTG). *Am Heart J*. 2010 Jul;160(1):80-87.e3.
87. **076A.** Roe MT, Messenger JC, Weintraub WS, et al. Treatments, trends, and outcomes of acute myocardial infarction and percutaneous coronary intervention. *JACC*. 2010 Jul 20;56(4):254-63.
88. **007A.** Lopes RD, Peterson ED, Chen AY, et al. Antithrombotic strategy in non-ST-segment elevation myocardial infarction patients undergoing percutaneous coronary intervention: insights from the ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Registry. *JACC Cardiovasc Interv*. 2010 Jun;3(6):669-77.
89. **008A.** Glickman SW, Cairns CB, Chen AY, et al. Delays in fibrinolysis as primary reperfusion therapy for acute ST-segment elevation myocardial infarction. *Am Heart J*. 2010 Jun;159(6):998-1004.e2.
90. **100A.** Glickman SW, Cairns CB, Chen AY, et al. Delays in fibrinolysis as primary reperfusion therapy for acute ST-segment elevation myocardial infarction. *Am Heart J*. 2010 Jun;159(6):998-1004.e2.
91. **026A.** Kadakia MB, Desai NR, Alexander KP, et al. Use of Anticoagulant Agents and Risk of Bleeding Among Patients Admitted With Myocardial Infarction: A Report From the NCDR ACTION Registry GWTG. *JACC Cardiovasc Interv*. 2010;3;1166-1177.
92. **017A.** Parikh SV, de Lemos JA, Jessen ME, et al. Timing of in-hospital coronary artery bypass graft surgery for non-ST-segment elevation myocardial infarction patients results from the National Cardiovascular Data Registry ACTION Registry-GWTG (Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With The Guidelines). *JACC Cardiovasc Interv*. 2010 Apr;3(4):419-27.
93. **012A.** Fox CS, Muntner P, Chen AY, et al. Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: a report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network registry. *CIRC*. 2010 Jan 26;121(3):357-65.
94. **044A-A.** Peterson ED, Roe MT, Rumsfeld JS, et al. A call to ACTION (acute coronary treatment and intervention outcomes network): a national effort to promote timely clinical feedback and support continuous quality improvement for acute myocardial infarction. *CIRC Cardiovasc Qual Outcomes*. 2009 Sep;2(5):491-9.
95. **006A.** Roe MT, Chen AY, Cannon CP, et al. Temporal changes in the use of drug-eluting stents for patients with non-ST-Segment-elevation myocardial infarction undergoing percutaneous coronary

intervention from 2006 to 2008: results from the can rapid risk stratification of unstable angina patients suppress Adverse outcomes with early implementation of the ACC/AHA guidelines (CRUSADE) and acute coronary treatment and intervention outcomes network-get with the guidelines (ACTION-GWTG) registries. CIRC: Cardiovasc Qual Outcomes. 2009 Sep;2(5):414-20.

96. **002A.** Diercks DB, Kontos MC, Chen AY, et al. Utilization and impact of pre-hospital electrocardiograms for patients with acute ST-segment elevation myocardial infarction: data from the NCDR (National Cardiovascular Data Registry) ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Registry. JACC. 2009 Jan 13;53(2):161-6.
97. **005A.** Cudnik MT, Frank Peacock W, Diercks DB, et al. Prehospital electrocardiograms (ECGs) do not improve the process of emergency department care in hospitals with higher usage of ECGs in non-ST-segment elevation myocardial infarction patients. Clin Cardiol. 2009 Dec;32(12):668-75.
98. **034A.** Leonardi S, Chen AY, Charachalou SM, et al. Limitations of using cardiac catheterization rates to assess the quality of care for patients with non-ST-segment elevation myocardial infarction. Am Heart J. 2012;164:502-8.
99. **49.** Matthews R, Fonarow GC, Li S, et al. Comparison of performance on Hospital Compare process measures and patient outcomes between hospitals that do and do not participate in Acute Coronary Treatment and Intervention Outcomes Network Registry–Get With The Guidelines. AHJ. 2016; Vol. 175, p1–8
100. **52.** Wayangankar SA, et al. Trends in use of anti-thrombotic agents and outcomes in patients with non-ST-segment elevation myocardial infarction (NSTEMI) managed with an invasive strategy, Indian Heart J. (2016)

## **IN PRESS**

1. **148. Neeland: Impact of Body Mass Index and Extreme Obesity on Long Term Outcomes in Older Adults with ST-Segment Elevation Myocardial Infarction: Results from the NCDR (National Cardiovascular Data Registry)**
2. **100. Doll: Current patterns of anti-platelet treatment among acute myocardial infarction patients on home clopidogrel therapy**

**PUBLISHED**

1. **196.** Jacob A. Doll, Dadi Dai, Matthew T. Roe, John C. Messenger, Matthew W. Sherwood, Abhiram Prasad, Ehtisham Mahmud, John S. Rumsfeld, Tracy Y. Wang, Eric D. Peterson, Sunil V. Rao. Assessment of Operator Variability in Risk-Standardized Mortality Following Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions Apr 2017, 10 (7) 672-682.
2. **244B.** Masoudi FA, Curtis JP, Desai, NR; PCI Appropriateness in New York. JACC. 2017; 69 (10): 1243-1246
3. **327.** Sapontis, J., Marso, SP, Cohen, DJ, et al.;The Outcomes, Patient Health Status, and Efficiency IN Chronic Total Occlusion Hybrid Procedures registry: rationale and design; CAD; 2017, 28(2): 110-119
4. **242.** Resnic FS, Majithia A, Marinac-Dabic D, Robbins S, Ssemaganda, et al.; Registry-Based Prospective, Active Surveillance of Medical-Device Safety. NEJM. 2017;376:526-35
5. **393P/156.** Amin AP, Patterson M, House JA, et al; Costs Associated With Access Site and Same-Day Discharge Among Medicare Beneficiaries Undergoing Percutaneous Coronary Intervention: An Evaluation of the Current Percutaneous Coronary Intervention Care Pathways in the United States; JACC:Cardiovascular Interventions, 2/27/2017, Volume 10; Issue 4; Pages 342-351
6. **325.** Alnasser SM, Bagai A, Jolly SS, Cantor WJ, Dehghani P, Rao SV, Cheema AN. Transradial approach for coronary angiography and intervention in the elderly: A meta-analysis of 777,841 patients. Int J Cardiol. 2017 Feb 1;228:45-51.
7. **367P.** Rymer, JA, Harrison, RW, Dai, D, et al; Trends in Bare-Metal Stent Use in the United States in Patients Aged  $\geq 65$  Years (from the CathPCI Registry); American Journal of Cardiology; 10/1/2016; Volume 118; Issue 7; Pages 959-966
8. **224.** Karrowni, W, Vora, AN, Dai, D, et al; Blood Transfusion and the Risk of Acute Kidney Injury Among Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention; CIRC:CI; 2016;9:e003279
9. **466P.** Motivala, AA, Parikh, V, Roe, M, et al; Predictors, Trends, and Outcomes (Among Older Patients  $>65$  Years of Age) Associated With Beta-Blocker Use in Patients With Stable Angina Undergoing Elective Percutaneous Coronary Intervention Insights From the NCDR Registry; JACC:CI; 2016; Volume 9; No. 16; Pgs 1639-1648
10. **468P.** Baber, U; Giustino, G; Wang, T; et al.; Comparisons of the uptake and in-hospital outcomes associated with second-generation drug-eluting stents between men and women: results from the CathPCI Registry; Coronary Artery Disease; 2016/9; Volume 27, Issue 6; Page 442–448
11. **272.** Schulman-Marcus, J, Feldman, DN, Rao, SV, et al; Characteristics of Patients Undergoing Cardiac Catheterization Before Noncardiac Surgery: A Report From the National Cardiovascular Data Registry CathPCI Registry; JAMA Internal Medicine; Online First; 3/28/2016
12. **212.** Vora, AN, Dai, D, Gurm, H, et al; Temporal Trends in the Risk Profile of Patients Undergoing Outpatient Percutaneous Coronary Intervention A Report from the National Cardiovascular Data Registry's CathPCI Registry; Circulation: Cardiovascular Interventions; March 8, 2016; Volume 9; Issue 3;e003070

13. **354P.** Vora, AN, Peterson, ED, McCoy, LA, et al, The Impact of Bleeding Avoidance Strategies on Hospital-Level Variation in Bleeding Rates Following Percutaneous Coronary Intervention: Insights From the National Cardiovascular Data Registry CathPCI Registry; JACC:CI; 4/25/2016; Vol. 9; No. 8; Page 771-779
14. **286P.** Kohsaka S, Miyata H, Ueda I, et al. An international comparison of patients undergoing percutaneous coronary intervention: A collaborative study of the National Cardiovascular Data Registry (NCDR) and Japan Cardiovascular Database–Keio interhospital Cardiovascular Studies (JCD-KiCS). American Heart Journal, December 2015, Volume 170, Issue 6, Pages 1077-1085
15. **365P.** Anderson L, Dai D, Miller AL, et al. Percutaneous Coronary Intervention for Older Adults Who Present with Syncope and Coronary Artery Disease? Insights from the National Cardiovascular Data Registry®. AHJ.6/2016; Vol 176; pages 1-9
16. **502P.** Wimmer, NJ, Secemsky, EA, Mauri, L, et al.; Effectiveness of Arterial Closure Devices for Preventing Complications With Percutaneous Coronary Intervention: An Instrumental Variable Analysis; 4/8/2016
17. **270P.** Wang TY, McCoy LA, Bhatt DL, et al.; Multivessel vs culprit-only percutaneous coronary intervention among patients 65 years or older with acute myocardial infarction; American Heart Journal, Volume 172, February 2016, Pages 9-18
18. **394P.** Safley DM et al. Impact of Glycoprotein IIb/IIIa Inhibition in Contemporary Percutaneous Coronary Intervention for Acute Coronary Syndromes: Insights From the National Cardiovascular Data Registry. JACC: Cardiovascular Interventions, Volume 8, Issue 12, October 2015, Pages 1574-1582
19. **467P.** Tracy Y. Wang, MD, MHS, MSC, Cindy Grines, MD, Rebecca Ortega, MS, et al. Women in Interventional Cardiology: Update in Percutaneous Coronary Intervention Practice Patterns and Outcomes of Female Operators From the National Cardiovascular Data Registry. Catheterization and Cardiovascular Interventions August 10, 2015. Published online ahead of print. DOI: 10.1002/ccd.26118.
20. **535P.** Amneet Sandhu, MD; Lisa A. McCoy, Smita I. Negi, MD; et al. Utilization of Mechanical Circulatory Support in Patients Undergoing Percutaneous Coronary Intervention: Insights From the NCDR. Circulation. 2015; published online before print August 18 2015, doi:10.1161/CIRCULATIONAHA.114.014451
21. **421P.** Michael P. Thomas, Craig S. Parzynski, Jephtha P. Curtis, Hitinder Gurm, et al. Percutaneous Coronary Intervention Utilization and Appropriateness across the United States. PLOS ONE. PLOS ONE | DOI:10.1371/journal.pone.0138251 September 17, 2015.
22. **437P.** Boyden TF, Joynt KE, McCoy L, et al.; Collaborative quality improvement vs public reporting for percutaneous coronary intervention: A comparison of percutaneous coronary intervention in New York vs Michigan; American Heart Journal; 2015; 170; 1227-1233
23. **504P.** Kadakia MB, Desai NR, Alexander KP, et al.; Use of Anticoagulant Agents and Risk of Bleeding Among Patients Admitted With Myocardial Infarction; JACC: Cardiovascular Interventions; 12/2015; Vol 3; No. 11; Pages 1166-1177.

24. **521P.** Dasari TW, Saucedo JF, Krim S, et al..Clinical Characteristics and in-hospital Outcomes of Heart Transplant Recipients with Allograft Vasculopathy Undergoing Percutaneous Coronary Intervention: Insights from The National Cardiovascular Data Registry; American Heart Journal; December 2015; Volume 170, Issue 6, Pages 1086-1091.
25. **443P.** Desai NR, Bradley SM, Parzynski CS, et al. Appropriate Use Criteria for Coronary Revascularization and Trends in Utilization, Patient Selection, and Appropriateness Of Percutaneous Coronary Intervention, JAMA, 2015, November, 09
26. **264.** Desai NR, Parzynski CS, Krumholz HM, et al. Patterns of Institutional Review of Percutaneous Coronary Intervention Appropriateness and the Effect on Quality of Care and Clinical Outcomes, JAMA Internal Medicine, 2015, November 09
27. **334.** Dehmer GJ, Jennings J, Madden RA, et al. The National Cardiovascular Data Registry Voluntary Public Reporting Program: An Interim Report From the NCDR Public Reporting Advisory Group. J Am Coll Cardiol. Published online November 18, 2015. doi:10.1016/j.jacc.2015.11.001
28. **534P.** Wayangankar SA, Bangalore S, McCoy LA, et al. Temporal Trends and Outcomes of Patients Undergoing Percutaneous Coronary Interventions for Cardiogenic Shock in the Setting of Acute Myocardial Infarction: A Report from the CathPCI Registry, JACC:CI, 03-2016, Vol: 9, No. 4
29. **378P.** Paul N. Fiorilli, Karl E. Minges, Jephtha P.Curtis, et al. Association of Physician Certification in Interventional Cardiology with In-Hospital Outcomes of Percutaneous Coronary Intervention. Circulation. Published online before print September 18, 2015, doi: 10.1161/CIRCULATIONAHA.115.017523
30. **253P-A:** Brennan J. Safety and Clinical Effectiveness of Drug-Eluting Stents for Saphenous Vein Graft Stenting in Older Individuals: Results from the Medicare-linked National Cardiovascular Data Registry® CathPCI Registry® (2005-2009)
31. **403P.** Krishna G. Aragam, MD, MS, Dadi Dai, PHD, Hitinder Gurm, M.D., et al. Gaps in Referral to Cardiac Rehabilitation of Patients Undergoing Percutaneous Coronary Intervention in the United States. J Am Coll Cardiol May 19 2015;65:2079–88.
32. **351P.** Matthew A. Cavender, MD, MPH, Karen E. Joynt, MD, MPH, Craig S. Parzynski, MSc, Hitinder S. Gurm, MD, et al. State Mandated Public Reporting and Outcomes of Percutaneous Coronary Intervention in the United States. Am J Cardiol 2015;115:1494e1501
33. **356P-C:** Connie N. Hess, MD, MHS, Mitchell W. Krucoff, MD, Sunil V. Rao, MD, et al. Comparison of quality-of-life measures after radial versus femoral artery access for cardiac catheterization in women: Results of the Study of Access Site for Enhancement of Percutaneous Coronary Intervention for Women quality-of-life substudy. Am Heart J May 4, 2015;0:1-9)
34. **448P:** Rajesh V. Swaminathan, MD,\* Sunil V. Rao, MD,y Lisa A. McCoy, et al. Hospital Length of Stay and Clinical Outcomes in Older STEMI Patients After Primary PCI A Report From the National Cardiovascular Data Registry. J Am Coll Cardiol Mar 31 2015;65:12;1161–71.

35. **346P:** John A Spertus, Carole Decker, Elizabeth Gialde, et al. Precision medicine to improve use of bleeding avoidance strategies and reduce bleeding in patients undergoing percutaneous coronary intervention: prospective cohort study before and after implementation of personalized bleeding risks. *BMJ* 24 March, 2015; 350 doi: <http://dx.doi.org/10.1136/bmj.h1302>.
36. **253P-B:** J. Matthew Brennan, Wesam Al-Hejily, David Dai, et al. Three-Year Outcomes Associated With Embolic Protection in Saphenous Vein Graft Intervention Results in 49 325 Senior Patients in the Medicare-Linked National Cardiovascular Data Registry CathPCI Registry. *Circ Cardiovasc Interv.* Feb 25, 2015;8:e001403. DOI: 10.1161/CIRCINTERVENTIONS.114.001403.
37. **447P.** Emmanouil S. Brilakis, Subhash Banerjee, Dimitri Karpaliotis, et al. Procedural Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention A Report From the NCDR (National Cardiovascular Data Registry). *J Am Coll Cardiol Interv.* 2015;8(2):245 doi:10.1016/j.jcin.2014.08.014.
38. **405P.** Herbert D. Aronow, Hitinder S. Gurm, James C. Blankenship, et al. Middle-of-the-Night Percutaneous Coronary Intervention and its Association With Percutaneous Coronary Intervention Outcomes Performed the Following Day: An Analysis From the National Cardiovascular Data Registry. *J Am Coll Cardiol Interv* 2015;8:49–56.
39. **215P-M.** Kevin J. Anstrom, J. Matthew Brennan, Eric L. Eisenstein, et al. Examination of the Treatment Selection Process in a Multicenter Observational Study. *Circ Cardiovasc Qual Outcomes.* 2014;7:764-769; originally published online August 12, 2014.
40. **315P-B.** Brahmajee K Nallamothu, Sharon-Lise T Normand, Yongfei Wang, Timothy P Hofer, et al. Relation between door-to-balloon times and mortality after primary percutaneous coronary intervention over time: a retrospective study. *Lancet.* 2014 Nov 19. pii: S0140-6736(14)61932-2. doi: 10.1016/S0140-6736(14)61932-2. [Epub ahead of print]
41. **336P-B.** Zugui Zhang, PHD, Paul Kolm, PHD, Maria V. Grau-Sepulveda, MD, MPH, et al. Cost-Effectiveness of Revascularization Strategies: The ASCERT Study. *J Am Coll Cardiol* 2015;65:1–11.
42. **372P.** Thomas T. Tsai, MD, MSc; Uptal D. Patel, MD; Tara I. Chang, MD; et al. Validated Contemporary Risk Model of Acute Kidney Injury in Patients Undergoing Percutaneous Coronary Interventions: Insights From the National Cardiovascular Data Registry Cath-PCI Registry. *JAHA* 2014 December 16;Vol 3(6); doi:10.1161/JAHA.114.001380.
43. **362P.** Sherwood MW, Brennan MJ, Ho KK, et al. The Impact of Extreme-Risk Cases on Hospitals' Risk-Adjusted Percutaneous Coronary Intervention Mortality Ratings. *J Am Coll Cardiol Interv.* Published online December 10, 2014. doi:10.1016/j.jcin.2014.07.025
44. **341P-B.** Hess CN, Rao SV, McCoy LA, et al. Identification of Hospital Outliers in Bleeding Complications After Percutaneous Coronary Intervention. *Circ Cardiovasc Qual Outcomes.* 2015;8:00-00. DOI: 10.1161/CIRCOUTCOMES.113.000749.
45. **318P.** Yeh RW, Czarny MJ, Normand ST, et al. Evaluating the Generalizability of a Large Streamlined Cardiovascular Trial: Comparing Hospitals and Patients in the Dual Antiplatelet Therapy Study Versus the National Cardiovascular Data Registry. *Circ Cardiovasc Qual Outcomes.* Originally published November 16, 2014. doi: 10.1161/CIRCOUTCOMES.114.001239

46. **386P.** Steven M. Bradley, MD, MPH; John A. Spertus, MD, MPH; Kevin F. Kennedy, MS; et al. Patient Selection for Diagnostic Coronary Angiography and Hospital-Level Percutaneous Coronary Intervention Appropriateness: Insights From the National Cardiovascular Data Registry. *JAMA Intern Med.* doi:10.1001/jamainternmed.2014.3904. Published online August 25, 2014.
47. **356P-B.** Sunil V. Rao, MD,\* Connie N. Hess, MD, MHS,\* Britt Barham, BA et al. A Registry-Based Randomized Trial Comparing Radial and Femoral Approaches in Women Undergoing Percutaneous Coronary Intervention: The SAFE-PCI for Women (Study of Access Site for Enhancement of PCI for Women) Trial. *JACC Cardiovasc Interv.* 2014 August; 7(8):857-867.
48. **452P.** Steven M. Bradley, Sunil V. Rao, Jephtha P. Curtis, et al. Change in Hospital-Level Use of Transradial Percutaneous Coronary Intervention and Periprocedural Outcomes: Insights from the National Cardiovascular Data Registry. *Circ Cardiovasc Qual Outcomes.* 2014; CIRCOUTCOMES 114.001020, published online before print June 4 2014, doi:10.1161/CIRCOUTCOMES.114.001020
49. **398P.** Connie N. Hess, Eric D. Peterson, Megan L. Neely, et al. The Learning Curve for Transradial Percutaneous Coronary Intervention among Operators in the United States: A Study from the National Cardiovascular Data Registry. *CIRCULATIONAHA.* 113.006356 Published online before print April 22, 2014, doi: 10.1161/CIRCULATIONAHA.113.006356
50. **390P.** Manesh R. Patel, David Dai, Adrian F. Hernandez, et al. Prevalence and predictors of non-obstructive coronary artery disease identified with coronary angiography in contemporary clinical practice. *American Heart Journal*, Volume 167, Issue 6, June 2014, Pages 846-852.e2 doi:10.1016/j.ahj.2014.03.001
51. **317P.** Mouin S. Abdallah, John A. Spertus, Brahmajee K. Nallamothu, et al. Symptoms and Angiographic Findings of Patients Undergoing Elective Coronary Angiography Without Prior Stress Testing. Published online before print, May 16, 2014; *Am J Cardiol* 2014 doi:10.1016/j.amjcard.2014.04.047
52. **382P.** Connie N. Hess, Sunil V. Rao, David Dai, et al. Predicting target vessel revascularization in older patients undergoing percutaneous coronary intervention in the drug-eluting stent era, *American Heart Journal*, Volume 167, Issue 4, April 2014, Pages 576-584.e2, ISSN 0002-8703, doi:10.1016/j.ahj.2013.12.017.
53. **357P.** Beau M. Hawkins, MD; Lisa A. McCoy, MS; Megan Neely, PhD, et al. Impact of Academic Year Timing on PCI Outcomes at Training Institutions. *JACC.* March 18, 2014;63:10;1025-30.
54. **348P.** Matthew W. Sherwood, MD; Yongfei Wang, MS; Jephtha P. Curtis, MD; et al. Patterns and Outcomes of Red Blood Cell Transfusion in Patients Undergoing Percutaneous Coronary Intervention. *JAMA.* 2014;311(8):836-843. doi:10.1001/jama.2014.980.
55. **375P-B.** Connie N. Hess, Lisa A. McCoy, Hesha J. Duggirala, et al. Sex-Based Differences in Outcomes After Percutaneous Coronary Intervention for Acute Myocardial Infarction: A Report From TRANSLATE-ACS. *J Am Heart Assoc.* 2014; 3: e000523 originally published February 7, 2014, doi: 10.1161/JAHA.113.000523

56. **244P.** Navdeep Gupta, MBBSa,\* , Michael C. Kontos, MD<sup>b</sup>, Aditi Gupta, MBBS<sup>c</sup>, et al. Characteristics and Outcomes in Patients Undergoing Percutaneous Coronary Intervention Following Cardiac Arrest (from the NCDR). Published online before print. *Am J Cardiol* 2014. doi:10.1016/j.amjcard.2013.12.014
57. **268P-A.** Thomas T. Tsai, Uptal D. Patel, Tara I. Chang, et al. Contemporary Incidence, Predictors, and Outcomes of Acute Kidney Injury in Patients Undergoing Percutaneous Coronary Interventions: Insights From the NCDR Cath-PCI Registry. *J Am Coll Cardiol Interv* 2014;7:1–9.
58. **241P.** Chee Tang Chin, John C. Messenger, David Dai, Comparison of percutaneous coronary intervention for previously treated versus de novo culprit lesions in acute myocardial infarction patients: insights from the National Cardiovascular Data Registry. *Am Heart J* 2014;0:1-8.e1
59. **330P.** Chan PS, Rao SV, Bhatt DL, et al. Patient and Hospital Characteristics Associated with Inappropriate Percutaneous Coronary Interventions. *J Am Coll Cardiol*. Published online September 18, 2013. doi:10.1016/j.jacc.2013.07.086
60. **215P-F.** Kutcher MA, Brennan JM, Rao SV, et al. Comparative effectiveness of drug-eluting stents on long-term outcomes in elderly patients treated for in-stent restenosis: A report from the national cardiovascular data registry. *Catheterization and Cardiovascular Interventions* 00:00–00 (2013). Published online before print November 12, 2013. DOI: 10.1002/ccd.25108
61. **327P.** Michael C. Kontos, Yongfei Wang, Sarwat I. Chaudhry, et al. Lower Hospital Volume Is Associated With Higher In-Hospital Mortality in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment –Elevation Myocardial Infarction: A Report From the NCDR. *Circ Cardiovasc Qual Outcomes*. November 2013. Published online ahead of print. doi: 10.1161/CIRCOUTCOMES.113.000233.
62. **341P-A.** S. Rao, L. McCoy, J. Spertus, et al. An Updated Bleeding Model to Predict the Risk of Post-Procedure Bleeding Among Patients Undergoing Percutaneous Coronary Intervention: A Report Using an Expanded Bleeding Definition From the National Cardiovascular Data Registry CathPCI Registry. *JACC Cardiovasc Interv*. 2013 September;6(6):897-904.
63. **315P-A.** Menees DS, Peterson ED, Wang Y, et al. Door-to-balloon time and mortality among patients undergoing primary PCI. *N Engl J Med*. 2013 Sep 5;369(10):901-9. doi: 10.1056/NEJMoa1208200.
64. **356P-A.** Hess CN, Rao SV, Kong DF, et al. Embedding a randomized clinical trial into an ongoing registry infrastructure: Unique opportunities for efficiency in design of the Study of Access site For Enhancement of Percutaneous Coronary Intervention for Women (SAFE-PCI for Women). *Am Heart J* 2013;0:1-8.e1.)
65. **349P.** Payvar S, Kim S, Rao SV, et al. In-Hospital Outcomes of Percutaneous Coronary Interventions in Extremely Obese and Normal-Weight Patients: Findings From the NCDR (National Cardiovascular Data Registry). *J Am Coll Cardiol* 2013;62:692–6).
66. **159P-B.** Borden WB, Spertus JA, Mushlin AI, et al. Antianginal Therapy Before Percutaneous

67. **368P.** Brennan JM, Curtis JP, Dai D, et al. Enhanced Mortality Risk Prediction With a Focus on High-Risk Percutaneous Coronary Intervention Results From 1,208,137 Procedures in the NCDR. *J Am Coll Cardiol Interv.* August 2013;6(8):790-799. doi:10.1016/j.jcin.2013.03.020
68. **280P.** Fazel R, Curtis J, Wang Y, et al. Determinants of fluoroscopy time for invasive coronary angiography and percutaneous coronary intervention: Insights from the NCDR®. *Catheter Cardiovasc Interv.* Article first published online: 24 JUL 2013. doi: 10.1002/ccd.24996
69. **215P-P.** Shah BR, McCoy LA, Federspiel JJ et al. Use of Stress Testing and Diagnostic Catheterization After Coronary Stenting Association of Site-Level Patterns With Patient Characteristics and Outcomes in 247,052 Medicare Beneficiaries. July 2013; *JACC*, 62(5):439-446. doi:10.1016/j.jacc.2013.02.093
70. **369P.** Dmitriy N. Feldman, Rajesh V. Swaminathan, Lisa A. Kaltenbach, MS, et al. Adoption of Radial Access and Comparison of Outcomes to Femoral Access in Percutaneous Coronary Intervention An Updated Report from the National Cardiovascular Data Registry (2007–2012). *Circulation.* 2013;127:2295-2306.
71. **215P-E.** Kumar RS, Douglas PS, Peterson ED, et al. Effect of Race and Ethnicity on Outcomes With Drug-Eluting and Bare Metal Stents Results in 423 965 Patients in the Linked National Cardiovascular Data Registry and Centers for Medicare & Medicaid Services Payer Databases. *Circulation.* 2013 Apr 2;127(13):1395-403. doi: 10.1161/CIRCULATIONAHA.113.001437.
72. **306P.** Daugherty, S.L., Thompson, L.E., Kim, S., et al. Patterns of Use and Comparative Effectiveness of Bleeding Avoidance Strategies in Men and Women Following Percutaneous Coronary Interventions: An Observational Study from the National Cardiovascular Data Registry®, *Journal of the American College of Cardiology* (2013), doi: 10.1016/j.jacc.2013.02.030. Published online ahead of print. March 27, 2013.
73. **295P.** Chhatriwalla AK, Amin AP, Kennedy KF, et al. Association between bleeding events and in-hospital mortality after percutaneous coronary intervention. *JAMA.* 2013 Mar 13;309(10):1022-9. doi: 10.1001/jama.2013.1556.
74. **446P.** Nallamothu BK, Spertus JA, Lansky AJ, et al. Comparison of Clinical Interpretation with Visual Assessment and Quantitative Coronary Angiography in Patients Undergoing Percutaneous Coronary Intervention in Contemporary Practice: The Assessing Angiography (A2) Project. *Circulation.* 2013 Mar 7. DOI:10.1161/CIRCULATIONAHA.113.001952 [Epub ahead of print].
75. **325P.** Swaminathan RV, Wang TY, Kaltenbach LA, et al. Non-System Reasons for Delay in Door- To-Balloon Time and Associated In-Hospital Mortality: A Report from the NCDR®. *J Am Coll Cardiol.* 2013 Mar 13. pii: S0735-1097(13)00684-0. doi: 10.1016/j.jacc.2012.11.073. [Epub ahead of print].
76. **413P.** Moussa I, Hermann A, Messenger JC, et al. The NCDR CathPCI Registry: a US national

perspective on care and outcomes for percutaneous coronary intervention. *Heart*. 2013 Mar;99(5):297-303.

- 77. 192P.** Harrison RW, Aggarwal A, Ou FS, et al. Incidence and outcomes of no-reflow phenomenon during percutaneous coronary intervention among patients with acute myocardial infarction. *Am J Cardiol*. 2013 Jan 15;111(2):178-84. doi: 10.1016/j.amjcard.2012.09.015. Epub 2012 Oct 27
- 78. 370P.** Baklanov DV, Kaltenbach LA, Marso SP, et al. The prevalence and outcomes of transradial percutaneous coronary intervention for ST-segment elevation myocardial infarction: analysis from the National Cardiovascular Data Registry (2007 to 2011). *J Am Coll Cardiol*. 2013 Jan 29;61(4):420-6.
- 79. 215P-D.** Hillegass WB, Patel MR, Klein LW, et al. Long-term outcomes of older diabetic patients after percutaneous coronary stenting in the United States: a report from the National Cardiovascular Data Registry, 2004 to 2008. *J Am Coll Cardiol*. 2012 Dec 4;60(22):2280-9.
- 80. 296P.** Dattilo PB, Prasad A, Honeycutt E, et al. Contemporary patterns of fractional flow reserve and intravascular ultrasound use among patients undergoing percutaneous coronary intervention in the United States: insights from the National Cardiovascular Data Registry. *J Am Coll Cardiol*. Dec 4;60(22):2337-9.
- 81. 248P.** Parikh NI, Honeycutt EF, Roe MT, et al. Left and codominant coronary artery circulations are associated with higher in-hospital mortality among patients undergoing percutaneous coronary intervention for acute coronary syndromes: report From the National Cardiovascular Database Cath Percutaneous Coronary Intervention (CathPCI) Registry. *Circ Cardiovasc Qual Outcomes*. 2012 Nov;5(6):775-82.
- 82. 344P.** Dehmer GJ, Weaver D, Roe MT, et al. A contemporary view of diagnostic cardiac catheterization and percutaneous coronary intervention in the United States: a report from the CathPCI Registry of the National Cardiovascular Data Registry, 2010 through June 2011. *J Am Coll Cardiol*. 2012 Nov 13;60(20):2017-31.
- 83. 215P-H.** Patel MR, Marso SP, Dai D, et al. Comparative effectiveness of drug-eluting versus bare-metal stents in elderly patients undergoing revascularization of chronic total coronary occlusions: results from the National Cardiovascular Data Registry, 2005-2008.
- 84. 215P-S.** Federspiel JJ, Mudrick DW, Shah BR, et al. Patterns and predictors of stress testing modality after percutaneous coronary stenting: data from the NCDR(®). *JACC Cardiovasc Imaging*. 2012 Oct;5(10):969-80.
- 85. 215P-I.** Anderson ML, Peterson ED, Brennan JM, et al. Short- and long-term outcomes of coronary stenting in women versus men: results from the National Cardiovascular Data Registry Centers for Medicare & Medicaid services cohort. *Circulation*. 2012 Oct 30;126(18):2190-9.
- 86. 215P-O.** Mudrick DW, Shah BR, McCoy LA, et al. Patterns of stress testing and diagnostic catheterization after coronary stenting in 250 350 medicare beneficiaries. *Circ Cardiovasc Imaging*

87. **249P.** Curtis JP, Geary LL, Wang Y, et al. Development of 2 registry-based risk models suitable for characterizing hospital performance on 30-day all-cause mortality rates among patients undergoing percutaneous coronary intervention. *Circ Cardiovasc Qual Outcomes*. 2012 Sep1;5(5):628-37.
88. **283P-B.** Rao SV, Dai D, Subherwal S, Weintraub WS, et al. Association between periprocedural bleeding and long-term outcomes following percutaneous coronary intervention in older patients. *JACC Cardiovasc Interv*. 2012 Sep;5(9):958-65.
89. **311P.** Amin AP, Spertus JA, Cohen DJ, et al. Use of drug-eluting stents as a function of predicted benefit: clinical and economic implications of current practice. *Arch Intern Med*. 2012 Aug 13;172(15):1145-52.
90. **010P.** Dodson JA, Wang Y, Chaudhry SI, Curtis JP. Bleeding-Avoidance Strategies and Outcomes in Patients >80 Years of Age With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention (from the NCDR® CathPCI Registry®). J. Curtis. *American Journal of Cardiology*. 2012 Jul;110(1):1-6.
91. **334P.** Tavaris DR, Wang Y, Jacobs S, et al. Bleeding and vascular complications at the femoral access site following percutaneous coronary intervention (PCI): an evaluation of hemostasis strategies. *J Invasive Cardiol*. 2012 Jul;24(7):328-34.
92. **215P-Q.** Mudrick D, Kaltenbach LA, Shah B, et al. Downstream testing and subsequent procedures after coronary computed tomographic angiography following coronary stenting in patients ≥65 years of age. *Am J Cardiol*. 2012 Sep 15;110(6):776-83.
93. **193P.** Owan TE, Roe MT, Messenger JC, Dai D, et al. Contemporary use of adjunctive thrombectomy during primary percutaneous coronary intervention for ST-elevation myocardial infarction in the United States. *Catheter Cardiovasc Interv*. 2012 Dec 1;80(7):1173-80. doi: 10.1002/ccd.24306. Epub 2012 Apr 17.
94. **283P-C.** Subherwal S, Peterson ED, Dai D, et al. Temporal trends in and factors associated with bleeding complications among patients undergoing percutaneous coronary intervention: a report from the National Cardiovascular Data CathPCI Registry. *J Am Coll Cardiol*. 2012 May 22;59(21):1861-9.
95. **331P.** Bradley SM, Chan PS, Spertus JA, et al. Hospital percutaneous coronary intervention appropriateness and in-hospital procedural outcomes: insights from the NCDR. *Circ Cardiovasc Qual Outcomes*. 2012 May;5(3):290-7.
96. **336P.** Weintraub WS, Grau-Sepulveda MV, Weiss JM, et al. Comparative effectiveness of revascularization strategies. *N Engl J Med*. 2012 Apr 19;366(16):1467-76.
97. **335P.** Weintraub WS, Grau-Sepulveda MV, Weiss JM, et al. Prediction of long-term mortality after percutaneous coronary intervention in older adults: results from the National Cardiovascular Data Registry. *Circulation*. 2012 Mar 27;125(12):1501-10.

98. **185P-A.** Cram P, House JA, Messenger JC, et al. Indications for percutaneous coronary interventions performed in US hospitals: a report from the NCDR®. *Am Heart J.* 2012 Feb;163(2):214-21.e1. doi: 10.1016/j.ahj.2011.08.024.
99. **185P-B.** Cram P, House JA, Messenger, et l. Percutaneous coronary intervention outcomes in US hospitals with varying structural characteristics: analysis of the NCDR®. *Am Heart J.* 2012 Feb;163(2):222-9.e1. doi: 10.1016/j.ahj.2011.10.010.
100. **215P-C.** Brennan JM, Dai D, Patel MR, et al. Characteristics and long-term outcomes of percutaneous revascularization of unprotected left main coronary artery stenosis in the United States: a report from the National Cardiovascular Data Registry, 2004 to 2008. *J Am Coll Cardiol.* 2012 Feb 14;59(7):648-54.
101. **252P.** Armstrong EJ, Feldman DN, Wang TY, et al. Clinical presentation, management, and outcomes of angiographically documented early, late, and very late stent thrombosis. *JACC Cardiovasc Interv.* 2012 Feb;5(2):131-40.
102. **215P-L.** Brennan JM, Peterson ED, Messenger JC, et al. Linking the National Cardiovascular Data Registry CathPCI Registry with Medicare claims data: validation of a longitudinal cohort of elderly patients undergoing cardiac catheterization. *Circ Cardiovasc Qual Outcomes.* 2012 Jan;5(1):134-40.
103. **195P.** Resnic FS, Wang TY, Arora N, et al. Quantifying the learning curve in the use of a novel vascular closure device: an analysis of the NCDR (National Cardiovascular Data Registry) CathPCI registry. *JACC Cardiovasc Interv.* 2012 Jan;5(1):82-9. doi: 10.1016/j.jcin.2011.09.017.
104. **215P-G.** Wang TY, Masoudi FA, Messenger JC, et al. Percutaneous coronary intervention and drug-eluting stent use among patients  $\geq 85$  years of age in the United States. *J Am Coll Cardiol.* 2012 Jan 10;59(2):105-12.
105. **009P.** Curtis JP, Rathore SS, Wang Y, et al. Use and Effectiveness of Intra-Aortic Balloon Pumps Among Patients Undergoing High Risk Percutaneous Coronary Intervention: Insights from the CathPCI Registry. *Circ Cardiovasc Qual Outcomes.* 2012 Mar 1;5(2):e16.
106. **233P.** Chin CT, Weintraub WS, Dai D, et al. Trends and predictors of length of stay after primary percutaneous coronary intervention: a report from the CathPCI registry. *Am Heart J.* 2011 Dec;162(6):1052-61.
107. **245P.** Stribling WK, Kontos MC, Abbate A, et al. Left circumflex occlusion in acute myocardial infarction (from the National Cardiovascular Data Registry). *Am J Cardiol.* 2011 Oct 1;108(7):959-63.
108. **290P.** Rao SV, Kaltenbach LA, Weintraub WS, et al. Prevalence and outcomes of same-day discharge after elective percutaneous coronary intervention among older patients. *JAMA.* 2011 Oct 5;306(13):1461-7.
109. **183P-B.** Brilakis ES, Rao SV, Banerjee S, et al. Percutaneous coronary intervention in native

arteries versus bypass grafts in prior coronary artery bypass grafting patients: a report from the National Cardiovascular Data Registry. *JACC Cardiovasc Interv.* 2011 Aug;4(8):844-50. doi: 10.1016/j.jcin.2011.03.018.

110.       **204P-B.** Douglas PS, Patel MR, Bailey SR, et al. Hospital variability in the rate of finding obstructive coronary artery disease at elective, diagnostic coronary angiography. *J Am Coll Cardiol.* 2011 Aug 16;58(8):801-9.
111.       **184P.** Deyell MW, Buller CE, Miller LH, et al. Impact of National Clinical Guideline recommendations for revascularization of persistently occluded infarct-related arteries on clinical practice in the United States. *Arch Intern Med.* 2011 Oct 10;171(18):1636-43. doi: 10.1001/archinternmed.2011.315. Epub 2011 Jul 11.
112.       **215P-B.** Tsai TT, Messenger JC, Brennan JM, et al. Safety and efficacy of drug-eluting stents in older patients with chronic kidney disease: a report from the linked CathPCI Registry-CMS claims database. *J Am Coll Cardiol.* 2011 Oct 25;58(18):1859-69.
113.       **247P.** Chan PS, Patel MR, Klein LW, et al. Appropriateness of percutaneous coronary intervention. *JAMA.* 2011 Jul 6;306(1):53-61.
114.       **159P-A.** Borden, WB, Redberg, RF, Mushlin, AI, et al. Patterns and Intensity of Medical Therapy in Patients Undergoing Percutaneous Coronary Intervention: W. Borden, et al. *JAMA*, May 11, 2011; 305(8):1882-1889.
115.       **144P.** Burjonrappa SC, Varosy PD, Rao SV, et al. Survival of Patients Undergoing Rescue Percutaneous Coronary Intervention. *JACC: Cardiovasc Interv* 2011. V4:1;42-50.
116.       **174P.** Wang, TY, Peterson, ED, Ou, FS, et al. Door-to-balloon times for patients with ST-segment elevation myocardial infarction requiring interhospital transfer for primary percutaneous coronary intervention: A report from the National Cardiovascular Data Registry. *Am Heart J.*2011;161(1): 76-83.
117.       **183P-A.** Brilakis ES, Wang TY, Rao SV, et al. Frequency and predictors of drug-eluting stent use in saphenous vein bypass graft percutaneous coronary interventions: a report from the American College of Cardiology National Cardiovascular Data CathPCI registry. *JACC Cardiovasc Interv.* 2010 Oct;3(10):1068-73. doi: 10.1016/j.jcin.2010.07.009.
118.       **197P.** Maddox TM, Ho PM, Roe M, et al. Utilization of secondary prevention therapies in patients with nonobstructive coronary artery disease identified during cardiac catheterization: insights from the National Cardiovascular Data Registry Cath-PCI Registry. *Circ Cardiovasc Qual Outcomes.* 2010 Nov;3(6):632-41.
119.       **163P.** Krone, RJ, Rao, SV, Dai, D., et al. Acceptance, Panic, and Partial Recovery: The Pattern of Usage of Drug-Eluting Stents After Introduction in the U.S. (A Report From the American College of Cardiology/National Cardiovascular Data Registry). R.J. Krone, *JACC: Cardiovasc Interv* 2010;3(9):903-910.

120.       **040P.** Lin GA, Redberg RF, Anderson HV, et al. Impact of Changes in Clinical Practice Guidelines on Assessment of Quality of Care. *Medical Care*: August 2010 - Volume 48 - Issue 8 - pp 733-738.
121.       **261P.** Amin AP, Marso SP, Rao SV, et al. Cost-effectiveness of targeting patients undergoing percutaneous coronary intervention for therapy with bivalirudin versus heparin monotherapy according to predicted risk of bleeding. *Circ Cardiovasc Qual Outcomes*. 2010 Jul;3(4):358-65.
122.       **226P.** Marso SP, Amin AP, House JA, et al. Association between use of bleeding avoidance strategies and risk of periprocedural bleeding among patients undergoing percutaneous coronary intervention. *JAMA*. 2010 Jun 2;303(21):2156-64.
123.       **178P.** Peterson ED, Dai D, DeLong ER , et al. Contemporary Mortality Risk Prediction for Percutaneous Coronary Intervention: Results from 588,398 Procedures in the National Cardiovascular Data Registry. *JACC*. Mar 31, 2010; published online ahead of print;doi:10.1016/j.jacc.2010.02.005
124.       **204P-A.** Patel MR, Peterson ED, Dai D, et al. Low diagnostic yield of elective coronary angiography. *N Engl J Med*. 2010 Mar 11;362(10):886-95.
125.       **007P.** Cardarelli F, Bellasi A, Ou FS, et al. Combined Impact of Age and Estimated Glomerular Filtration Rate on In-Hospital Mortality After Percutaneous Coronary Intervention for Acute Myocardial Infarction (from the American College of Cardiology National Cardiovascular Data Registry). *Am J Cardiol* 2009 Mar 15: 103(6): 766-771.
126.       **085P.** Cavender MA, Milford-Beland S, Roe MT, et al. Prevalence, predictors, and in-hospital outcome of non-infarct artery Intervention during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Results from the National Cardiovascular Data Registry (NCDR). *Am J Cardiol* 2009;104:507–513.
127.       **149P.** Aggarwal A, Dai D, Rumsfeld JS, et al. Incidence and Predictors of Stroke Associated with Percutaneous Coronary Intervention. *Am J Cardiol* 2009;104:349–353
128.       **092P.** Kutcher MA, Klein LW, Ou FS, et al. Percutaneous Coronary Interventions in Facilities without Cardiac Surgery On-Site: A Report from the National Cardiovascular Data Registry (NCDR). *J Am Coll Cardiol* 2009;59:16-24.
129.       **122P.** Grantham JA, Marso SP, Spertus J, et al. Chronic total occlusion angioplasty in the United States. *JACC Cardiovasc Interv*. 2009;2(6):479-486.
130.       **124P.** Mehta SK, Frutkin AD, Lindsey JB, et al. Bleeding in Patients Undergoing Percutaneous Coronary Intervention: The Development of a Clinical Risk Algorithm From the National Cardiovascular Data Registry. *Circ Cardiovasc Intervent*. 2009;2:222-229.
131.       **001P-A.** SS Rathore, JP Curtis, BK Nallamothu, et al. Association of door-to-balloon time and mortality in patients admitted to hospital with ST elevation myocardial infarction: national cohort

study. BMJ 2009;338:b1807.

- 132. 130P.** Akhter N, Milford-Beland S, Roe MT, et al. Gender Differences Among Patients with Acute Coronary Syndromes (ACS) Undergoing Percutaneous Coronary Intervention (PCI) in the American College of Cardiology-National Cardiovascular Data Registry. AHJ 2009;157:141-8.
- 133. 164P.** Mehta, RH, Ou, FS, Peterson, ED, et al. Clinical Significance of Post-Procedural Thrombolysis In Myocardial Infarction Flow in Patients With Cardiogenic Shock Undergoing Primary Percutaneous Coronary Intervention. JACC Cardiovasc Interv Jan 2009;2(1):56-64.
- 134. 008P.** Kao J, Vicuna R, Rumsfeld J; et al. Effect of Insurance Status on Use of Drug-Eluting Stents versus Bare Metal Stents in Patients Undergoing Elective Percutaneous Coronary Intervention. American Heart Journal (AHJ) Dec 2008;V156(6):1133-1140.
- 135. 135P.** Dixon WC 4th, Wang TY, Dai D, et al. Anatomic Distribution of the Culprit Lesion in Patients With Non-ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention. J Am Coll Cardiol, 2008;v15(16):1347-1351.
- 136. 084P.** Rao SV, Ou FS, Wang TY, et al. Trends in the Prevalence and Outcomes of Radial and Femoral Approaches to Percutaneous Coronary Intervention. JACC Cardiovasc Interv Aug 2008;V1:379-386.
- 137. 138P.** Singh M, Peterson ED, Milford-Beland S, et al. Validation of the Mayo clinic risk score for in-hospital mortality after percutaneous coronary interventions using the national cardiovascular data registry. Circ Cardiovasc Interv. 2008 Aug;1(1):36-44. .
- 138. 083P.** Wang TY, Peterson ED, Dai D, et al. Patterns of Cardiac Marker Surveillance after Elective Percutaneous Coronary Intervention: Implications for the Use of Peri-procedural Myocardial Infarction as a Quality Metric. J. Am. Coll. Cardiol. 2008;51;2068-2074.
- 139. 002P.** Chakrabarti A, Krumholz HM, Wang TY, et al. Time-to-reperfusion in patients undergoing interhospital transfer for primary percutaneous coronary intervention in the U.S: an analysis of 2005 and 2006 data from the National Cardiovascular Data Registry. Am J Cardiol 2008 Jun 24;51(25):2442-3.
- 140. 039P.** Brener SJ, Milford-Beland S, Roe MT, et al. Culprit-only or multivessel revascularization in patients with acute coronary syndromes; An ACC-NCDR report. Am Heart J 2008; 155:140-6.
- 141. 151P.** Wang TY, Peterson ED, Dai D, et al. Patterns of Cardiac Marker Surveillance After Elective Percutaneous Coronary Intervention and Implications for the Use of Periprocedural Myocardial Infarction as a Quality Metric: A Report From the National Cardiovascular Data Registry (NCDR). JACC. May 27 2008;51(21):2068-2074.
- 142. 143P.** Aggarwal A, Dai D, Rumsfeld JS, et al. Impact of Home Warfarin Use on the Treatment and Outcomes of Patients Undergoing Percutaneous Coronary Intervention. Am J Cardiol 2008;101:1413-1417.

- 143. 047P.** Shaw LJ, Shaw RE, Merz CN, et al. Impact of Ethnicity and Gender Differences on Angiographic Coronary Artery Disease Prevalence and In-Hospital Mortality in the American College of Cardiology National Cardiovascular Data Registry. *Circulation* 2008;117:1787-1801.
- 144. 134P.** Ting HH, Roe MT, Gersh BJ, et al. Factors Associated with Off-label Use of Drug Eluting Stents in Patients with ST-elevation Myocardial Infarction. *Am J Cardiol* February 2008;101: 286-292.
- 145. 087P.** Mehta SK, Frutkin AD, Milford-Beland S, et al. Utilization of distal embolic protection in saphenous vein graft interventions (an analysis of 19,546 patients in the American College of Cardiology-National Cardiovascular Data Registry). *Am J Cardiol.* 2007;100(7):1114–1118.
- 146. 006P.** Risk-Adjusted Mortality Analysis of Percutaneous Coronary Interventions by American College of Cardiology/American Heart Association Guidelines Recommendations. HV Anderson, RE Shaw, RG Brindis, CR McKay, LW Klein, RJ Krone, KK Ho, JS Rumsfeld, SC Smith Jr., WS Weintraub. *Am J Cardiol* 2007; 99:189–196.
- 147. 022P.** Dehmer GJ, Kutcher MA, Dey SK, et al. Frequency of Percutaneous Coronary Interventions at Facilities without On-Site Cardiac Surgical Backup—A Report from the American College of Cardiology–National Cardiovascular Data Registry (ACC-NCDR®). *Am J Cardiol* 2007; 99:329–332.
- 148. 037P.** Tavaris DR, Gallauresi B, Brindis RG. "Hemostatic Devices" Chapter in: *Medical Device Epidemiology and Surveillance*. John Wiley & Sons, Ltd. England 2007, pages 379-394.
- 149. 115P-C.** Tavaris DR, Gallauresi BA, Dey S, et al. Risk of local adverse events by gender following cardiac catheterization. D. Tavaris et al. *Pharmacoepidemiology and Drug Safety* 2007;16:125–131.
- 150. 103P.** Rao SV, Shaw RE, Brindis RG, et al. Patterns and outcomes of drug-eluting coronary stent use in clinical practice. *Am Heart J.* 2006 Aug; 152(2):321–6.
- 151. 030P.** Huang HW, Brent BN, Shaw RE. Trends in Percutaneous Versus Surgical Revascularization of Unprotected Left Main Coronary Stenosis in the Drug-Eluting Stent Era—A Report from the American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR). *Catheter Cardiovasc Interv* 2006; 68:867–872.
- 152. 038P.** Krone RJ, Shaw RE, Klein LW, et al. Ad Hoc Percutaneous Coronary Intervention (PCI) in Patients with Stable Coronary Artery Disease—A Study of Prevalence, Safety, and Variation in Use from the American College of Cardiology—National Cardiovascular Data Registry. *Catheter Cardiovasc Interv* 2006; 68(5):696–703.
- 153. 098P.** Rao SV, Shaw RE, Brindis RG, et al. On- versus Off-Label Use of Drug-Eluting Coronary Stents in Clinical Practice: Report from the ACC-NCDR. *Am J Cardiol* 2006; 97(10):1478–1481.

154.       **061P.** Brindis RG, Dehmer GJ. Continuous quality improvement in the cardiac catheterization laboratory - Are the benefits worth the cost and effort? *Circulation*. Feb 14 2006; 113(6):767–770. Editorial.
155.       **115P-B.** Tavaris DR, Dey S, Albrecht-Gallauresi B, et al. Risk of Local Adverse Events following Cardiac Catheterization by Hemostasis Device Use — Phase II. D. Tavaris, et al. *J Invasive Cardiol* 2005;17:644–650.
156.       **053P.** Klein LW, Shaw RE, Krone RJ, et al. Mortality after Emergent PCI in Cardiogenic Shock Secondary to Acute Myocardial Infarction and Usefulness of a Mortality Prediction Model. *Am J Cardiol* 2005; 96(1):35–41.
157.       **158P.** Singh, M Peterson, ED, Roe, MT, et al. Trends in the Association between Age and In-Hospital Mortality Following PCI: National Cardiovascular Data Registry Experience. *Circ Cardiovasc Intervent* published online ahead of print Feb 10, 2009; DOI: 10.1161/CIRCINTERVENTIONS.108.826172
158.       **215P-A.** Douglas PS, Patel MR, Bailey SR, et al. Hospital variability in the rate of finding obstructive coronary artery disease at elective, diagnostic coronary angiography. *J Am Coll Cardiol*. 2011 Aug 16;58(8):801-9.
159.       **216P-B.** Tsai TT, Maddox TM, Roe MT, et al. Contraindicated medication use in dialysis patients undergoing percutaneous coronary intervention. *JAMA*. 2009 Dec 9;302(22):2458-64.
160.       **018P.** Anderson HV, Shaw RE, Brindis RG, et al. Relationship between procedure indications and outcomes of percutaneous coronary interventions by the American College of Cardiology/American Heart Association Task Force Guidelines. *Circulation* 2005; 112(18):2786–2791.
161.       **073P-B.** Brindis, R.G., Fitzgerald, S., Anderson, H.V., et al. The American College of Cardiology- National Cardiovascular Data Registry™ (ACC-NCDR™): Building a National Clinical Data Repository. *JACC* June 15, 2001;37(8):2240–5.
162.       **123P.** Frutkin, AD, Lindsey, JB, Mehta, SK, et al. Drug-Eluting Stents and the Use of Percutaneous Coronary Intervention Among Patients With Class I Indications for Coronary Artery Bypass Surgery Undergoing Index Revascularization: Analysis From the NCDR (National Cardiovascular Data Registry). *JACC: Cardiovasc Interv*. July 2009;2(7): 614–21.
163.       **152P.** Kim MS, Wang TY, Dai D, et al. Association of previous coronary artery bypass graft surgery with door-to-balloon time and in-hospital outcomes: a report from the National Cardiovascular Data Registry (NCDR). *J Am Coll Cardiol*. 2008 Nov 11;52(20):1665-70. doi: 10.1016/j.jacc.2008.08.017.
164.       **156P.** Nallamothu BK, Wang Y, Bradley EH, et al. Comparing hospital performance in door-to- balloon time between the Hospital Quality Alliance and the National Cardiovascular Data Registry. *J Am Coll Cardiol*. 2007 Oct 9;50(15):1517-9.

165.       **227P.** Douglas PS, Brindis RG. President's page: a question of quality: why national benchmarking? *Am Coll Cardiol.* 2006 Mar 7;47(5):1076-8.
166.       **228P.** Habash-Bseiso DE, Rokey R, Berger CJ, et al. Accuracy of noninvasive ejection fraction measurement in a large community-based clinic. *Clin Med Res.* 2005 May;3(2):75-82.
167.       **229P.** Matheny ME, Ohno-Machado L, Resnic FS. Discrimination and calibration of mortality risk prediction models in interventional cardiology. *J Biomed Inform.* 2005 Oct;38(5):367-75. Epub 2005 Mar 26.
168.       **114P.** Dehmer GJ, Elma M, Hewitt K, Brindis RG. Bringing Measurement and Management Science to the Cath Laboratory: The ACC-NCDR and the Cardiac Catheterization Laboratory Continuous Quality Improvement Toolkit. *J Cardiovasc Manag* 2004; 15(6):20–6.
169.       **115P-A.** Tavriss DR, Gallauresi BA, Lin B, et al. Risk of Local Adverse Events Following Cardiac Catheterization by Hemostasis Device Use and Gender. *J Invasive Cardiol.* 2004 Sep;16(9):459-64.
170.       **109P.** Dehmer GJ, Hirshfeld JW, Oetgen WJ, et al. CathKIT: Improving Quality in the Cardiac Catheterization Laboratory. *J Am Coll Cardiol* 2004; 43:893–9.
171.       **117P.** Shaw RE, Anderson HV, Brindis RG, et al. Updated Risk-Adjustment Mortality Model Using the Complete 1.1 Dataset from the ACC-NCDR. *J Invas Cardiol* 2003; 15(10):578–580.
172.       **049P.** Krone RJ, Shaw RE, Klein LW, et al. Evaluation of the American College of Cardiology/ American Heart Association and the Society for Coronary Angiography and Interventions Lesion Classification System in the Current 'Stent Era' of Coronary Interventions. *Am J Cardiol* 2003; 92:389–394.
173.       **066P.** Klein LW, Block P, Brindis RG, et al. Percutaneous Coronary Interventions in Octogenarians in the American College of Cardiology—National Cardiovascular Data Registry: Development of a Nomogram Predictive of In-Hospital Mortality. *J Am Coll Cardiol* 2002; 40(3):394–402.
174.       **064P.** Shaw RE, Anderson HV, Brindis RG, et al. Development of a Risk Adjustment Mortality Model Using the American College of Cardiology—National Cardiovascular Data Registry Experience: 1998-2000. *J Am Coll Cardiol* 2002; 39(7):1104–1112.
175.       **065P.** Anderson HV, Shaw RE, Brindis RG, et al. A Contemporary Overview of Percutaneous Coronary Interventions: The American College of Cardiology—National Cardiovascular Data Registry. *J Am Coll Cardiol* 2002; 39(7):1096–1103.
176.       **073P-A.** Brindis RG, Fitzgerald S, Anderson HV, et al. The ACC-NCDR: Building a National Clinical Data Repository. *J Am Coll Cardiol* 2001; 37(8): 2240–2245
177.       **118P.** Weintraub WS. Development of the American College of Cardiology National

178. **448P.** Swaminathan RV, Rao SV, McCoy LA, et al. Hospital Length of Stay and Clinical Outcomes in Older STEMI Patients After Primary PCI A Report From the National Cardiovascular Data Registry. J Am Coll Cardiol Mar 31 2015;65:12;1161–71.
179. **346P.** Spertus JA, Decker C, Gialde E, et al. Precision medicine to improve use of bleeding avoidance strategies and reduce bleeding in patients undergoing percutaneous coronary intervention: prospective cohort study before and after implementation of personalized bleeding risks. BMJ 24 March, 2015; 350 doi: <http://dx.doi.org/10.1136/bmj.h1302>.

### **IN PRESS**

1. Chui, P Correlation Among Hospital PCI Process Measures and Relationship with 30-day PCI Readmission and Mortality
2. Minges, K Development and validation of a simple risk score to predict 30-day readmission for percutaneous coronary intervention

## **ICD Registry™**

### **PUBLISHED**

1. **039-I.** Schneider PM, Pellegrini CN, Wang Y et al. Prevalence of Guideline-Directed Medical Therapy Among Patients Receiving Cardiac Resynchronization Therapy Defibrillator Implantation in the National Cardiovascular Data Registry During the Years 2006 to 2008. Am J Cardiol. 2014 Jun 15;113(12):2052-6.
2. **181-I.** Kramer DB, Kennedy KF, Spertus JA, et al. Mortality Risk Following Replacement Implantable Cardioverter-Defibrillator Implantation at End of Battery Life: Results from the NCDR® . Heart Rhythm. Volume 11, Issue 2, Pages 216-221, February 2014.
3. **135-I.** Dev S, Peterson PN, Wang Y, et al. Prevalence, Correlates, and Temporal Trends in Antiarrhythmic Drug Use at Discharge After Implantable Cardioverter Defibrillator Placement (from the National Cardiovascular Data Registry [NCDR]). (Am J Cardiol February 2014;113:314e320).
4. **089-I.** Dodson JA, Lampert R, Wang Y, et al. Temporal Trends in Quality of Care among ICD Recipients: Insights from the NCDR®. Circulation. 2013; published online before print November 5 2013, Circulation. 2014;129:580-586.
5. **098-I-A.** Akar JG, Bao H, Jones P, et al. Use of Remote Monitoring of Newly Implanted Cardioverter-Defibrillators: Insights from the Patient RElated Determinants of ICD Remote Monitoring (PREDICt RM) Study. Circulation. Originally published September 16, 2013. doi:

6. **130-I.** Hsu JC, Varosy PD, Bao H, et al. Cardiac Perforation From Implantable Cardioverter-Defibrillator Lead Placement: Insights From the National Cardiovascular Data Registry. *Circ Cardiovasc Qual Outcomes*. September 13, 2013; 6: 582-590.
7. **094-I-A.** Russo AM, Wang Y, Al-Khatib SM, et al. Patient, Physician, and Procedural Factors Influencing the Use of Defibrillation Testing during Initial Implantable Cardioverter Defibrillator Insertion: Findings from the NCDR. *PACE* 2013 Aug 26. doi: 10.1111.
8. **112-I.** Peterson PN, Greiner MA, Qualls LG, et al. QRS duration, bundle-branch block morphology, and outcomes among older patients with heart failure receiving cardiac resynchronization therapy. *JAMA*. 2013 Aug 14; 310(6):617-26. doi: 10.1001/jama.2013.8641.
9. **026-I-G.** Hess PL, Mi X, Curtis LH, et al. Follow-up of patients with new cardiovascular implantable electronic devices: Is adherence to the experts' recommendations associated with improved outcomes? *Heart Rhythm*. August 2013, Volume 10(8): 1127–1133. doi: 10.1016/j.hrthm.2013.06.009.
10. **120-I.** Kramer DB, Kennedy KF, Noseworthy PA, et al. Characteristics and Outcomes of Patients Receiving New and Replacement Implantable Cardioverter-Defibrillators: Results From the NCDR. *Circ Cardiovasc Qual Outcomes*. 2013 July, 6(4): 488-497.
11. **106-I.** Peterson PN, Varosy PD, Heidenreich PA, et al. Association of single- vs dual-chamber ICDs with mortality, readmissions, and complications among patients receiving an ICD for primary prevention. *JAMA*. 2013 May 15;309(19):2025-34.
12. **117-I.** Kremers MS, Hammill SC, Berul CI, et al. The National ICD Registry Report: Version 2.1 including leads and pediatrics for years 2010 and 2011. *Heart Rhythm*. April 2013, Pages e59-e65.
13. **158-I.** Russo AM, Stainback RF, Bailey SR, Epstein AE, Heidenreich PA, Jessup M, Kapa S, Kremers MS, Lindsay BD, Stevenson LW. ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCMR 2013 appropriate use criteria for implantable cardioverter-defibrillators and cardiac resynchronization therapy: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, Heart Rhythm Society, American Heart Association, American Society of Echocardiography, Heart Failure Society of America, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. *J Am Coll Cardiol* March 13, 2013; 61: 1318–68.
14. **015-I.** Lampert R, Wang Y, Curtis J. Variation among hospitals in selection of higher-cost, “higher tech,” implantable cardioverter-defibrillators: Data from the National Cardiovascular

15. **026-I-B.** Al-Khatib SM, Hellkamp A, Bardy GH, et al. Survival of patients receiving a primary prevention implantable cardioverter-defibrillator in clinical practice vs clinical trials. JAMA. 2013 Jan 2;309(1):55-62.
  
16. **161-I.** Masoudi FA, Go AS, Magid DJ, et al. Longitudinal Study of Implantable Cardioverter-Defibrillators: Methods and Clinical Characteristics of Patients Receiving Implantable Cardioverter-Defibrillators for Primary Prevention in Contemporary Practice. Circ Cardiovasc Qual Outcomes. 2012 Nov;5(6):e78-85.
  
17. **093-I.** Hsu JC, Varosy PD, Bao H, Wang Y, Curtis JP, Marcus, GM. Low Body Mass Index but Not Obesity is Associated with In-Hospital Adverse Events and Mortality Among Implantable Cardioverter-Defibrillator Recipients: Insights from the NCDR®. J Am Heart Assoc. 2012; 1: e003863 originally published October 30, 2012.
  
18. **051-I.** Farmer SA, Tuohy EJ, Small DS, et al. Impact of Community Wealth on Use of Cardiac-Resynchronization Therapy With Defibrillators for Heart Failure Patients. Circ Cardiovasc Qual Outcomes. 2012. Nov;5(6):798-807.
  
19. **084-I.** Eapen ZJ, Al-Khatib S, Lopes RD, et al. Are Racial/Ethnic Gaps in the Use of Cardiac Resynchronization Therapy Narrowing?: An Analysis of 107,096 Patients From the National Cardiovascular Data Registry's ICD Registry. J Am Coll Cardiol. 2012 Oct 16;60(16):1577-8.
  
20. **054-I.** Cheng A, Wang Y, Berger RD et al. Electrophysiology Studies in Patients Undergoing ICD Implantation: Findings from the NCDR®. Pacing Clin Electrophysiol. 2012 Aug;35(8):912-8.
  
21. **063-I.** Matlock DD, Peterson PN, Wang Y, et al. Variation in Use of Dual-Chamber Implantable Cardioverter-Defibrillators: Results From the National Cardiovascular Data Registry. Arch Intern Med. 2012;172(8):634-641.
  
22. **062-I.** Bhatt P, Curtis J, Wang Y, et al. Impact of a Recent Lead Recall on Utilization of Implantable Cardioverter Defibrillators: Data from the NCDR ICD Registry™. J Cardiovasc Electrophysiol. 2012 Aug;23(8):861-5.
  
23. **018-I-B.** Freeman JV, Wang Y, Curtis JP, et al. Physician Procedure Volume and Complications of Cardioverter-Defibrillator Implantation. CIRC 2012;125 57-64.
  
24. **065-I.** Miller AL, Wang Y, Curtis J, et al. Optimal Medical Therapy Use Among Patients

25. **049-I-B.** Tsai V, Goldstein MK, Hsia HH, et al. Influence of Age on Perioperative Complications Among Patients Undergoing Implantable Cardioverter-Defibrillators for Primary Prevention in the United States. Circ Cardiovasc Qual Outcomes. 2011; 4: 549-556.
26. **027-I.** Dewland TA, Pellegrini CN, Wang Y, et al. Dual-Chamber Implantable Cardioverter-Defibrillator Selection Is Associated With Increased Complication Rates and Mortality Among Patients Enrolled in the NCDR Implantable Cardioverter-Defibrillator Registry. JACC. Vol. 58, No. 10, 2011, 1007-1013.
27. **036-I.** Tsai V, Goldstein MK, Hsia HH, et al. Age Differences in Primary Prevention Implantable Cardioverter-Defibrillator Use in U.S. Individuals. J Am Geriatr Soc. 2011 Sep;59(9):1589-95.
28. **043-I.** Haines DE, Wang Y, Curtis J. Implantable Cardioverter-Defibrillator Registry Risk Score Models for Acute Procedural Complications or Death After Implantable Cardioverter-Defibrillator Implantation. CIRC. 2011;123:2069-2076.
29. **059-I.** Wei S, Loyo-Berríos NI, Haigney MC, et al. Elevated B-Type Natriuretic Peptide Is Associated With Increased In-Hospital Mortality or Cardiac Arrest in Patients Undergoing Implantable Cardioverter-Defibrillator Implantation. Circ Cardiovasc Qual Outcomes. 2011 May;4(3):346-54.
30. **038-I.** Matlock DD, Kutner JS, Emsermann CB, et al. Regional Variations in Physicians' Attitudes and Recommendations Surrounding Implantable Cardioverter-Defibrillators. Journal of Cardiac Failure. Volume 17, Issue 4, April 2011, Pages 318-324.
31. **028-I.** Matlock DD, Peterson PN, Heidenreich PA, et al. Regional Variation in the Use of Implantable Cardioverter-Defibrillators for Primary Prevention: Results From the National Cardiovascular Data Registry. Circ Cardiovasc Qual Outcomes 2011;4;114-121.
32. **026-I-A.** Al-Khatib SM, Hellkamp A, Curtis J, et al. Non-evidence-based ICD implantations in the United States. JAMA. 2011 Jan 5;305(1):43-9.
33. **050-I.** Cheng A, Wang Y, Curtis JP, Varosy PD. Acute lead dislodgements and in-hospital mortality in patients enrolled in the national cardiovascular data registry implantable cardioverter defibrillator registry. J Am Coll Cardiol. 2010 Nov 9;56(20):1651-6.
34. **018-I-A.** Freeman JV, Wang Y, Curtis JP, et al. The Relation Between Hospital Procedure

35. **077-I.** Hammill SC, Kremers MS, Stevenson LW, et al. Review of the Registry's Fourth Year, Incorporating Lead Data and Pediatric ICD Procedures, and Use as a National Performance Measure Original Research Article. Heart Rhythm. 2010 Sep;7(9):1340-5.
36. **041-I.** Fein AS, Wang Y, Curtis JP, et al. Prevalence and Predictors of Off-Label Use of Cardiac Resynchronization Therapy in Patients Enrolled in the National Cardiovascular Data Registry Implantable Cardiac-Defibrillator Registry Original Research Article. JACC. Volume 56, Issue 10, 31 August 2010, Pages 766-773.
37. **034-I.** Aggarwal A, Wang Y, Rumsfeld JS, et al. Clinical characteristics and in-hospital outcome of patients with end-stage renal disease on dialysis referred for implantable cardioverter-defibrillator implantation. Heart Rhythm. 2009 Nov;6(11):1565-71.
38. **061-I.** Hammill SC, Kremers MS, Kadish AH, et al. Review of the ICD Registry's third year, expansion to include lead data and pediatric ICD procedures, and role for measuring performance. Heart Rhythm. 2009 Sep;6(9):1397-401.
39. **017-I-B.** Daugherty SL, Peterson PN, Wang Y, et al. Use of implantable cardioverter defibrillators for primary prevention in the community: do women and men equally meet trial enrollment criteria? Am Heart J. 2009 Aug;158(2):224-9.
40. **025-I.** Curtis JP, Luebbert JJ, Wang Y, et al. Association of physician certification and outcomes among patients receiving an implantable cardioverter-defibrillator. JAMA. 2009; 301(16): 021661-70.
41. **017-I-A.** Peterson PN, Daugherty SL, Wang Y, et al. Gender differences in procedure-related adverse events in patients receiving implantable cardioverter-defibrillator therapy. Circulation. 2009 3; 119 (8): 1078-84.
42. **004-I.** Farmer SA, Kirkpatrick JN, Heidenreich PA, et al. Ethnic and racial disparities in cardiac resynchronization therapy. Heart Rhythm. 2009; 6(3): 325-31.
43. **045-I.** Hammill SC, Kremers MS, Stevenson LW, et al. Review of the Registry's Second Year, Data Collected, and Plans to Add Lead and Pediatric ICD Procedures. Heart Rhythm. 2008; 5(9): 1359-1363.
44. **044-I-B.** Hammill SC, Stevenson LW, Kadish AH, et al. Review of the Registry's First Year, Data Collected, and Future Plans. Heart Rhythm. 2007; 4 (9): 1260-1263.

45. **044-I-A.** Hammill SC, Phurrough S, Brindis R. The National ICD Registry: Now and into the future. *Heart Rhythm*. 2006; 3 (4); 471-473.
46. **159-I.** Dodson JA, Reynolds MR, Bao H, Al-Khatib SM, Peterson ED, Kremers MS, Mirro MJ, Curtis JP, Developing a Risk Model for in-Hospital Adverse Events following ICD Implantation: A Report from the NCDR® Registry, *J Am Coll Cardiol*. 2013, doi: 10.1016/j.jacc.2013.09.079.
47. **026-I-C.** Al-Khatib S, Hellkamp A, Fonarow G, et al. Association Between Prophylactic Implantable Cardioverter-Defibrillators and Survival in Patients With Left Ventricular Ejection Fraction Between 30% and 35%. *JAMA*. 2014; 311(21): 2209-2215.
48. **026-I-H.** Hess PL, Hellkamp AS, Peterson ED, et al. Survival after Primary Prevention Implantable Cardioverter-Defibrillator Placement Among Patients with Chronic Kidney Disease. *Circ Arrhythm Electrophysiol*. 2014; 7: 793-799.
49. **094-I-B.** Hsu JC, Marcus GM, Al-Khatib SM, et al. Predictors of an Inadequate Defibrillation Safety Margin at ICD Implantation. *J Am Coll Cardiol* 2014; 64: 256–64.
50. **162-I.** Masoudi FM, Mi X, Curtis LH, et al. Comparative Effectiveness of Cardiac Resynchronization Therapy With an Implantable Cardioverter-Defibrillator Versus Defibrillator Therapy Alone. *Ann Intern Med*. 2014; 160: 603-611.
51. **163-I-A.** Setoguchi S, Warner L, Stewart GC, et al. Influence of healthy candidate bias in assessing clinical effectiveness for implantable cardioverter-defibrillators: cohort study of older patients with heart failure. *Br Med J*. 2014; 348: g2866.
52. **122-I.** Steckman D, Varosy PD, Parzynski CS, Masoudi FA, Curtis JP, Sauer WH, Nguyen DT. In-Hospital Complications Associated With Reoperations of Implantable Cardioverter Defibrillators. *Am J of Cardiol*. 2014; 114 (3): 419-426.
53. **137-I-A.** Zusterzeel R, Curtis JP, Caños DA, et al. Sex-Specific Mortality Risk by QRS Morphology and Duration in Patients Receiving CRT: Results From the NCDR. *J Am Coll Cardiol*. 2014; 64(9): 887.
54. **147-I.** Borne RT, Peterson PN, Greenlee R, et al. Temporal Trends in Patient Characteristics and Outcomes Among Medicare Beneficiaries Undergoing Primary Prevention Implantable Cardioverter-Defibrillator Placement in the United States, 2006–2010: Results from the National Cardiovascular Data Registry’s Implantable Cardioverter-Defibrillator Registry. *Circulation*. 2014; 130 (10): 845-853.

55. **110-I.** Prutkin JM, Reynolds MR, Bao H, et al. Rates of and Factors Associated with Infection in 200,909 Medicare Implantable Cardioverter-Defibrillator Implants: Results from the NCDR. *Circulation*. 2014; 130: 1037-1043.
56. **113-I.** Khazanie P, Hammill BG, Qualls LG, et al. Clinical Effectiveness of Cardiac Resynchronization Therapy vs Medical Therapy Alone Among Patients With Heart Failure: Analysis of the ICD Registry and ADHERE. *Circulation: Heart Failure*. 2014; 7: 926-934.
57. **139-I.** Hsu JC, Varosy PD, Parzynski CS, et al. Procedure timing as a predictor of in-hospital adverse outcomes from implantable cardioverter-defibrillator implantation: Insights from the National Cardiovascular Data Registry. *Am Heart J*. 2015; 169 (1): 45-52.e3.
58. **62 (150-I B).** Jordan CP, Freedberg V, Wang Y, et al. Implant and Clinical Characteristics for Pediatric and Congenital Heart Patients in the National Cardiovascular Data Registry Implantable Cardioverter Defibrillator Registry. *Circ Arrhythmia Electrophysiol*. 2014; 7: 1092-1100.
59. **12 (026-I-E).** Zeitler EP, Hellkamp AS, Fonarow GC, et al. Primary Prevention Implantable Cardioverter Defibrillators and Survival in Older Women. *JACC HF*. 2015; 3(2): 159-167.
60. **13 (026-I-F).** Pokorney SD, Hellkamp AS, Yancy CW, et al. Primary Prevention Implantable Cardioverter-Defibrillators in Older Racial and Ethnic Minority Patients. *Circ Arrhythmia Electrophysiol*. 2015; 8: 145-151.
61. **23 (042-I).** Ghanbari H, Nallamothu BK, Wang Y, and Curtis JP. Antithrombotic Therapy and Outcomes After ICD Implantation in Patients With Atrial Fibrillation and Coronary Artery Disease: An Analysis From the National Cardiovascular Data Registry (NCDR). *J Am Heart Assoc*. 2015; 4:e001331.
62. **64 (157-I).** Hess PL, Greiner MA, Al-Khatib SM, et al. Same-Day Discharge and Risks of Mortality and Readmission After Elective ICD Placement for Primary Prevention. *J Am Coll Cardiol*. 2015;65(9):955-957.
63. **11 (026-I-D).** Pun PH, Hellkamp AS, Sanders GD, et al. Primary prevention implantable cardioverter defibrillators in end-stage kidney disease patients on dialysis: a matched cohort study. *Nephrol. Dial. Transplant*. (2014) doi: 10.1093/ndt/gfu274
64. **49 (108-I).** Heidenreich PA, Tsai V, Bao H, et al. Does Age Influence Cardiac Resynchronization Therapy Use and Outcome? *JACC HF*. 2015; 3(6): 497–504.
65. **67 (160-I).** Masoudi FA, Go AS, Magid DJ, et al. Age and Sex Differences in Long-Term Outcomes Following Implantable Cardioverter-Defibrillator Placement in Contemporary Clinical Practice: Findings From the Cardiovascular Research Network. *J Am Heart Assoc*. 2015;4:e002005.
66. **71 (163-I-B 2).** Chen C, Stevenson LW, Stewart GC, et al. Real world effectiveness of primary implantable cardioverter defibrillators implanted during hospital admissions for exacerbation of heart failure or other acute co-morbidities: cohort study of older patients

with heart failure. *BMJ* 2015;351:h3529.

- 67. 59B (137-IB).** Zusterzeel R, Spatz ES, Curtis JP, et al. Cardiac Resynchronization Therapy in Women Versus Men; Observational Comparative Effectiveness Study From the National Cardiovascular Data Registry. *Circ Cardiovasc Qual Outcomes*. 2015;8:S4-S11.
- 68. 46 (103-I).** Russo AM, Daugherty SL, Masoudi FA, et al. Gender and outcomes after primary prevention implantable cardioverter-defibrillator implantation: Findings from the National Cardiovascular Data Registry (NCDR). *Am Heart J*. 2015; 170 (2): 330-8.
- 69. 48 (107-I).** Heidenreich PA, Tsai V, Curtis J, et al. A validated risk model for 1-year mortality after primary prevention implantable cardioverter defibrillator placement. *Am Heart J*. 2015; 170 (2): 281-289.e2.
- 70. 79 (192-I).** Friedman D, Singh J, Curtis J, et al. Comparative Effectiveness of Cardiac Resynchronization Therapy with Defibrillator versus Defibrillator Alone in Heart Failure Patients with Moderate to Severe Chronic Kidney Disease. *JACC*. 2015; 65(10S)
- 71. 28 (049-I-A).** Kaiser DW, Tsai V, Heidenreich, PA, et al. Defibrillator Implantations for Primary Prevention in the United States: Inappropriate Care or Inadequate Documentation? Insights from the National Cardiovascular Data ICD Registry. *HRJ*. 2015
- 72. 8B (26-I-I).** Khazanie P, Hellkamp AS, Fonarow GC, et al. Association Between Comorbidities and Outcomes in Heart Failure Patients With and Without an Implantable Cardioverter-Defibrillator for Primary Prevention. *J Am Heart Assoc*. 2015;4:e002061.
- 73. 88A (98-I-B).** Akar JG, Bao H, Jones P, et al. Use of Remote Monitoring Is Associated with Lower Risk of Adverse Outcomes Among Patients with Implanted Cardiac Defibrillators. *Circ EP* 2015.
- 74. 74 (170-I).** Green AR, Leff B, Wang Y, et al. Geriatric Conditions in Patients Undergoing Defibrillator Implantation for Prevention of Sudden Cardiac Death Prevalence and Impact on Mortality *Circ Cardiovasc Qual Outcomes*. 2016 Jan;9(1):23-30.
- 75. 75 (172-1).** Khazanie P, Greiner MA, Al-Khatib SM, et al. Comparative Effectiveness of Cardiac Resynchronization Therapy Among Patients with Heart Failure and Atrial Fibrillation. *Circ Heart Failure*. 2016;9:e002324.
- 76. 78 (190-I).** Ranasinghe I, Parzynski CS, Freeman JAV, et al. Long-Term Risk for Device-Related Complications and Reoperations After Implantable Cardioverter-Defibrillator Implantation. *Annals of Internal Med*. 2016;165:20-29.
- 77. 101.** Friedman DJ, Parzynski CS, Varosy PD, et al. Trends and In-Hospital Outcomes Associated with Adoption of the Subcutaneous Implantable Cardioverter Defibrillator in the United States; *JAMA Cardiology Online*; September 7, 2016.
- 78. 093.** Zeitler EP, Wang Y, Dharmarajan K, et al. Outcomes 1 Year After Implantable

79. **079.** Friedman DJ, Singh JP, Curtis JP, et al. Comparative Effectiveness of CRT-D Versus Defibrillator Alone in HF Patients With Moderate-to-Severe Chronic Kidney Disease; *JACC* VOL .66, NO 23, 2015
80. **135.** Kramer DB, Reynolds MR, Normand S-L, et al. Hospice Use Following Implantable Cardioverter-Defibrillator Implantation in Older Patients Results From the National Cardiovascular Data Registry; *Circulation*. 2016;133:2030- 2037.
81. **74-I.** Green AR, Leff B, Wang Y, et al. Geriatric Conditions in Patients Undergoing Defibrillator Implantation for Prevention of Sudden Cardiac Death Prevalence and Impact on Mortality; *Circ Cardiovasc Qual Outcomes*. 2016;9:23-30
82. **100.** Echouffo-Tcheugui JB, Masoudi FA, Ba H, et al; Effect of Diabetes on Outcomes of Cardiac Resynchronization Therapy and Implantable Cardioverter-Defibrillator Therapy in People with Heart Failure; *Circ Arrhythm Electrophysiol*. 2016;9:e004132.
83. **121.** Friedman DJ, Bao H, Spatz ES, et al; Association Between Prolonged PR Interval and Outcomes of Cardiac Resynchronization Therapy: a Report from the National Cardiovascular Data Registry; *Circulation*. 2016; 134(21): 1617-1628.
84. **94.** Katz DF, Peterson PN, Bourne RT, et al; Survival After Secondary Prevention Implantable Cardioverter-Defibrillator Placement- An Analysis From the NCDR ICD Registry; *JACC: Clinical Electrophysiology*. 2017; 3(1): 20-28.
85. **96.** Betz JK, Katz DF, Peterson PN, et al; Outcomes Among Older Patients Receiving Implantable Cardioverter-Defibrillators for Secondary Prevention - An Analysis from the NCDR ICD Registry; *JACC*. 2017; 69(3): 265-274.
86. **124.** Bansal N, Szpiro A, Masoudi F, et al Kidney function and appropriateness of device therapies in adults with implantable cardioverter defibrillators. *Heart*. 2017;103(7):529-537.

## **IN PRESS**

1. **102.** Marzec, L. Hospital Variation in the Utilization of Cardiac Resynchronization Therapy among Eligible Patients Receiving an Implantable Cardioverter-Defibrillator: Insights from the NCDR.
2. **83.** Pokorney, S. Temporal Trends and Variations in the Use of Single Coil Versus Dual Coil ICD Leads

**PUBLISHED**

1. **53C.** Aronow, HD, Kennedy, KF, Wayangankar, SA, et al; Prescription of Guideline-Based Medical Therapies at Discharge After Carotid Artery Stenting and Endarterectomy: An NCDR Analysis; Stroke; 8/2016;47:00:00
2. **25C-A.** Giri J, Yeh RW, Kennedy KF, et al. Unprotected carotid artery stenting in modern practice. Catheter Cardiovasc Interv. 83:595–602 (2014).
3. **19C.** Brian G. Hynes, MD, Kevin F. Kennedy, MS, Nicholas J. Ruggiero, II, MD, et al. Carotid Artery Stenting for Recurrent Carotid Artery Restenosis After Previous Ipsilateral Carotid Artery Endarterectomy or Stenting: A Report From the National Cardiovascular Data Registry. JACC Cardiovasc Interv. February 2014. 7;2:180-6.
4. **25C-B.** Jay Giri, MD, MPH, Kevin F. Kennedy, MS, Ido Weinberg, MD, et al. Comparative Effectiveness of Commonly Used Devices for Carotid Artery Stenting An NCDR Analysis (National Cardiovascular Data Registry). JACC Cardiovasc Interv. February 2014. 7;2:171-7.
5. **01C.** Gruberg L, Jeremias A, Rundback JH, et al. Impact of glomerular filtration rate on clinical outcomes following carotid artery revascularization in 11,832 patients from the care registry(r). Catheter Cardiovasc Interv. 2013 Jun 29. doi: 10.1002/ccd.25101. [Epub ahead of print] PubMed PMID: 23813603.
6. **48C.** Neil J. Wimmer, John A. Spertus, Kevin F. Kennedy, et al. Clinical Prediction Model Suitable for Assessing Hospital Quality for Patients Undergoing Carotid Endarterectomy. J Am Heart Assoc. June 17, 2014. doi: 10.1161/JAHA.113.000728.
7. **15C-B.** Rajamani K, Kennedy KF, Ruggiero NJ, et al. Outcomes of carotid endarterectomy in the elderly: report from the national cardiovascular data registry. Stroke. 2013 Apr;44(4):1172-4. doi: 10.1161/STROKEAHA.111.000513. Epub 2013 Feb.
8. **24C.** Wayangankar SA, Abu-Fadel MS, Aronow HD, et al. Hemorrhagic and Ischemic Outcomes After Bivalirudin Versus Unfractionated Heparin During Carotid Artery Stenting: A Propensity Score Analysis From the NCDR. Circ Cardiovasc Interv. 2013 Mar 26. [Epub ahead of print]
9. **22C.** Mercado N, Cohen DJ, Spertus JA, et al. Carotid artery stenting of a contralateral occlusion and in-hospital outcomes: results from the CARE (Carotid Artery Revascularization and Endarterectomy) registry. JACC Cardiovasc Interv. 2013 Jan;6(1):59-64. doi: 10.1016/j.jcin.2012.09.009.
10. **32C.** Hawkins BM, Kennedy KF, Giri J, et al. Pre-procedural Risk Quantification for Carotid Stenting Using the CAS Score: A Report From the NCDR CARE Registry. J Am Coll Cardiol. 2012 Oct 23;60(17):1617-22. doi: 10.1016/j.jacc.2012.07.026. Epub 2012 Sep 19.
11. **11C-A.** Don CW, House J, White C, et al. Carotid revascularization immediately before urgent cardiac surgery practice patterns associated with the choice of carotid artery stenting or endarterectomy: a report from the CARE (Carotid Artery Revascularization and Endarterectomy) registry. JACC Cardiovasc

12. **09C.** Yeh RW, Kennedy K, Spertus JA, et al. Do postmarketing surveillance studies represent real- world populations? A comparison of patient characteristics and outcomes after carotid artery stenting. *Circulation*. 2011 Apr 5;123(13):1384-90. doi: 10.1161/CIRCULATIONAHA.110.991075. Epub 2011 Mar 21.
13. **17C.** Longmore RB, Yeh RW, Kennedy KF, et al. Clinical Referral Patterns for Carotid Artery Stenting Versus Carotid Endarterectomy : Results From the Carotid Artery Revascularization and Endarterectomy Registry. *Circ Cardiovasc Interv*. 2011;4:88-94
14. **13C.** Anderson HV, Rosenfield KA, White CJ, et al. Clinical features and outcomes of carotid artery stenting by clinical expert consensus criteria: a report from the CARE registry. *Catheter Cardiovasc Interv*. 2010 Mar 1;75(4):519-25. doi: 10.1002/ccd.22333.
15. **03C.** White CJ, Anderson HV, Brindis RG, et al. The Carotid Artery Revascularization and Endarterectomy (CARE) registry: objectives, design, and implications. *Catheter Cardiovasc Interv*. 2008 May 1;71(6):721-5. doi: 10.1002/ccd.21502.
16. **25C-C.** Giri J, Parikh SA, Kennedy KF, et al. Proximal Versus Distal Embolic Protection for Carotid Artery Stenting: A National Cardiovascular Data Registry Analysis. *J Am Coll Cardiol Interv* 2015;8:609–15.
17. **44C.** Beau M. Hawkins, Kevin F. Kennedy, Robert W. Yeh, et al. Hospital Variation in Carotid Stenting Outcomes. *J Am Coll Cardiol Interv*. 2015;8(6):858-863. doi:10.1016/j.jcin.2015.01.026.
18. **52C.** Siddharth A. Wayangankar, Kevin F. Kennedy, Faisal Latif, et al. Racial/Ethnic Variation in Carotid Artery Revascularization Utilization and Outcomes Analysis From the National Cardiovascular Data Registry. *Stroke*. 2015;46:1525-1532. DOI: 10.1161/STROKEAHA.115.009013

**IN PRESS**

**PUBLISHED**

1. **002M.** Martin GR, Beekman RH, Ing FF, et al. The IMPACT registry: IMproving Pediatric and Adult Congenital Treatments. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu. 2010;13(1):20-5.
2. **007M.** Moore JW, Vincent RN, Beekman RH, et al. Procedural Results and Safety of Common Interventional Procedures in Congenital Heart Disease: Initial Report From the National Cardiovascular Data Registry. J Am Coll Cardiol. 2014; 64(23):2439-2451. doi:10.1016/j.jacc.2014.09.045.
3. **003M.** Vincent RN, Moore J, Beekman III RH, et al. Procedural characteristics and adverse events in diagnostic and interventional catheterizations in paediatric and adult CHD: initial report from the IMPACT Registry. Cardiology in the Young; March 19, 2015; online before print; doi:10.1017/S1047951114002637.
4. **09M.** Jayaram N, Beekman RH, Benson L, et al., Adjusting for Risk Associated With Pediatric and Congenital Cardiac Catheterization: A Report From the NCDR IMPACT Registry; Circ; 2015; 132; 1863-1870
5. **08M.** Holzer R, Beekman R, Benson L, et al.; Characteristics and safety of interventions and procedures performed during catheterization of patients with congenital heart disease: early report from the national cardiovascular data registry; Cardiology in the Young; 2015
6. **19M.** Lewis, MJ, Kennedy, KF, Ginns, J, et al.; Procedural Success and Adverse Events in Pulmonary Artery Stenting: Insights From the NCDR; JACC, March 22, 2016, Volume 67, No. 11, pgs 1327-1335
7. **13M.** O'Byrne, ML; Gillespie, MJ; Kennedy, KF, et al; The influence of deficient retro-aortic rim on technical success and early adverse events following device closure of secundum atrial septal defects: An Analysis of the IMPACT Registry®; CCI; 5/18/2016
8. **18M/8.** Jayaram, N, Spertus, JA, O'Byrne, ML; Relationship between hospital procedure volume and complications following congenital cardiac catheterization: A report from the IMproving Pediatric and Adult Congenital Treatment (IMPACT) registry; AHJ; 1/2017; Vol 183; Pages 118-128
9. **14.** Stefanescu-Schmidt AC, Armstrong A, Kennedy KF, et al; Prediction of adverse events after catheter-based procedures in adolescents and adults with congenital heart disease in the IMPACT registry; EHJ; 2017/04/18; ehx200

**IN PRESS**

## PINNACLE Registry®

### **PUBLISHED**

1. **PINN-23B.** Maddox TM, Chan PS, Spertus JA, et al. Variation in CAD Secondary Prevention Prescription among Outpatient Cardiology Practices: Insights from the NCDR®. JACC. 2014; 63(6); 539-546.
2. **PINN-30.** Frederick MA, Singh T, Salami S, et al. First Steps: Exploring Use of a Prospective, Office-Based Registry as a Foundation for Quality Improvement in Cardiology Training. Journal of Graduate Medical Education. 2013; 5(4): 694-699.
3. **PINN-5.** Spinler SA, Cziraky MH, Tang F, et al. Patient Eligibility for Medication Therapy Management Services Within Practices Enrolled in the PINNACLE Registry™. American Health & Drug Benefits. 2013; 6(7):367-374.
4. **PINN-23A.** Peterson PN, Chan PS, Spertus JA, et al Practice-level Variation in use of Recommended Medications among Outpatients with Heart Failure: Insights from the NCDR PINNACLE Registry. Circ Heart Fail. 2013 Nov; 6(6):1132-8.
5. **PINN-29.** Subherwal, S, Patel MR, Tang F, et al. Socioeconomic Disparities in Use of Cardioprotective Medications Among Patients with Peripheral Artery Disease—An Analysis of the American College of Cardiology’s NCDR PINNACLE Registry®. JACC. 2013; (62)1:51-57.
6. **PINN-1.** Smolderen K, Spertus, JA, Tang F, Oetgen W, Borden WB, Ting HH, Chan PS. Treatment Differences by Health Insurance Among Outpatients with Coronary Artery Disease: Insights from the NCDR®. JACC. 2013;61(10).
7. **PINN-2.** Chan PS, Maddox TM, Tang F, et al. Practice-level variation in warfarin use among outpatients with atrial fibrillation (from the NCDR PINNACLE Program). American Journal of Cardiology. 2011;108:1136–1140.
8. **PINN-19.** May D, Fiocchi F, Kehoe K, et al. Quality Improvement of Cardiovascular Care in the Outpatient Setting: Implementation of the American College of Cardiology and National Cardiovascular Data Registry’s PINNACLE Registry in a Single - Specialty Practice. PEJ. 2011; 37:38-42.
9. **PINN-11.** Arnold SV, Spertus JA, Tang F, Krumholz HM, Borden WB, Farmer SA, Ting HH, Chan PS. Statin use in outpatients with obstructive coronary artery disease. Circulation. 2011;124:2405-2410.
10. **IC3-15.** The Improving Continuous Cardiac Care (IC3) Program and Outpatient Quality Improvement. P. Chan, W. Oetgen, J. Spertus. The American Journal of Medicine. 2010;123(3): 217- 219.
11. **Editorial related to IC3-16.** Scaling New Heights in Quality Improvement: The PINNACLE (Practice Innovation And Clinical Excellence) Program. Rao SV. Journal of the American College of Cardiology. 2010;56;15-17.

12. **IC3-16.** Cardiac performance measure compliance in outpatients. Chan PS, Oetgen WJ, Buchanan D, et al. *JACC*. 2010;56(1): 8-14.
13. **PINN-17.** Oetgen WJ, Mullen JB, Mirro MM. Cardiologists, the PINNACLE Registry, and the "Meaningful Use" of Electronic Health Records. *Journal of the American College of Cardiology*. 2011;57:1560-1563.
14. **PINN-21.** Erb BD, Allen J, Chamber L, et al. The PINNACLE Network™—Facilitating Quality of Care in Outpatient Cardiovascular Medicine. *US Cardiology*, 2011;8(1):12–5.
15. **PINN-27.** Oetgen WJ. Duelin' Registries. *Circ Cardiovasc Qual Outcomes*. 2011;4:483-485.
16. **PINN-28.** Oetgen WJ, Mullen JB, Mirro MM. Electronic Health Records, the PINNACLE Registry, and Quality Care. *Arch Intern Med*. 2011; 171: 954.
17. **PINN-36.** Glusenkamp NT, Oetgen WJ, Mullen B. The Million Hearts Initiative—Targeting Key Drivers of Cardiovascular Mortality from a Medical Specialty Society Perspective. *US Cardiology*. 2012; 9 (1): 66–70.
18. **PINN-4.** Goldsweig AM, Reid KJ, Gosch K, et al. Contemporary Use of Dual Anti-platelet Therapy for Preventing Cardiovascular Events. *Am J Manag Care*. 2014; 20 (8): 659-665.
19. **00064.** Maddox TM, Borden WB, Tang F, et al. Implications of the 2013 ACC/AHA Cholesterol Guidelines for Adults in Contemporary Cardiovascular Practice: Insights From the NCDR PINNACLE Registry. *J Am Coll Cardiol*. 2014; 64(21): 2183-2192.
20. **00065.** Borden WB, Maddox TM, Tang F, et al. Impact of the 2014 Expert Panel Recommendations for Management of High Blood Pressure on Contemporary Cardiovascular Practice: Insights From the National Cardiovascular Data Registry PINNACLE Registry. *J Am Coll Cardiol*. 2014; 64 (21): 2196-2203.
21. **33 (PINN-56).** Hira RS, Kennedy K, Nambi V, et al. Frequency and Practice-Level Variation in Inappropriate Aspirin Use for the Primary Prevention of Cardiovascular Disease: Insights From the National Cardiovascular Disease Registry's Practice Innovation and Clinical Excellence Registry. *J Am Coll Cardiol*. 2015; 65 (2): 111-121.
22. **27 (PINN-43).** Bandeali SJ, Gosch K, Alam M, et al. Coronary Artery Disease Performance Measures and Statin Use in Patients with Recent Percutaneous Coronary Intervention or Recent Coronary Artery Bypass Grafting (From the NCDR® PINNACLE Registry). *Am J Cardiol*. 2015; 115 (8): 1013-1018.
23. **25 (PINN-38).** Hsu JC, Chan PS, Tang F, et al. Differences in Anticoagulant Therapy Prescription in Patients with Paroxysmal Versus Persistent Atrial Fibrillation: Insights from the NCDR® PINNACLE Registry. *Am J Med*. 2015; 128 (6): 654.e1-654.e10.
24. **26 (PINN-40).** Hsu JC, Chan PS, Tang F, Maddox TM, Marcus GM. Oral Anticoagulant Prescription in Atrial Fibrillation Patients with a Low Risk of Thromboembolism: Insights from the NCDR® PINNACLE Registry.

25. **32 (PINN-48).** Eapen ZJ, Tang F, Jones PG, et al. Variation in performance measure criteria significantly affects cardiology practice rankings: Insights from the National Cardiovascular Data Registry's Practice Innovation and Clinical Excellence Registry. *Am Heart J*. 2015 Jun; 169 (6): 847-853.
26. **5 (PINN-6).** Spinler SA, Cziraky MJ, Willey VJ, et al. Frequency of Attainment of Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol Goals in Cardiovascular Clinical Practice (from the National Cardiovascular Data Registry PINNACLE Registry). 2015 *Am J Cardiol* 2015; 116:547e553.
27. **31 (PINN-47).** Virani SS, Maddox TM, Chan PS, et al. Provider Type and Quality of Outpatient Cardiovascular Disease Care: Insights From the NCDR PINNACLE Registry. *J Am Coll Cardiol*. 2015;66(16):1803-1812. doi:10.1016/j.jacc.2015.08.017
28. **60.** Wasfy JH, Kennedy KF, Chen JS, Ferris TG, Maddox TM, Yeh RW. Practice Variation in Triple Therapy for Patients With Both Atrial Fibrillation and Coronary Artery Disease: Insights From the ACC's National Cardiovascular Data Registry. *JACCCEP*. 2016;2(1):36-43. doi:10.1016/j.jacep.2015.08.010.
29. **28.** Fleming LM, Jones P, Chan PS, et al. Relationship of Provider and Practice Volume to Performance Measure Adherence for Coronary Artery Disease, Heart Failure, and Atrial Fibrillation: Results From the National Cardiovascular Data Registry. *Circ Cardiovasc Qual Outcomes*. 2016 Jan;9(1):48-54.
30. **37 (PINN-69).** Hsu JC, Maddox TM, Kennedy KF, et al. Oral Anticoagulant Therapy Prescription in Patients With Atrial Fibrillation Across the Spectrum of Stroke Risk: Insights From the NCDR PINNACLE Registry. *JAMA Cardiol*. Published online March 16, 2016.
31. **38.** Hsu JC, Maddox TM, Kennedy K, et al. Aspirin Instead of Oral Anticoagulant Prescription in Atrial Fibrillation Patients at Risk for Stroke. *J Am Coll Cardiol*. 2016; 67(25); 2913-2923.
32. **87.** Pokharel Y, Gosch K, Nambi V, et al. Practice Level Variation in Statin Use Among Patients with Diabetes. *J Am Coll Cardiol*. 2016; 68(12); 1368-1369.
33. **71.** Gehi, A. Factors associated with rhythm control treatment decisions in patients with atrial fibrillation—Insights from the NCDR PINNACLE registry

## **IN PRESS**

1. **86.** Pokharel, Y. Trends and Predictors of Statin Use Before and After the Publication of the 2013 American College of Cardiology/American Heart Association (ACC/AHA) Guideline on the Treatment of Blood Cholesterol: Insights from the NCDR® PINNACLE Registry
3. **130.** Bradley, S. Implications of the PEGASUS-TIMI 54 Trial for U.S. Cardiovascular Practice: Insights from the NCDR PINNACLE Registry
4. **90.** Maddox, T. Implications of the IMPROVE-IT Trial for U.S. Cardiovascular Practice: Insights from the NCDR PINNACLE Registry

## TVT Registry

### **PUBLISHED**

1. **08T.** DR Holmes, JM Brennan, JS Rumsfeld, et al. Clinical Outcomes at 1 Year Following Transcatheter Aortic Valve Replacement. *JAMA*. 2015;313(10):1019-1028. doi:10.1001/jama.2015.1474.
2. **Editorial:** Rumsfeld JS, Holmes DR, Stough WG, et al. Insights From the Early Experience of the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. *J Am Coll Cardiol Interv*. Published online February 19, 2015. doi:10.1016/j.jcin.2014.09.022
3. **Editorial:** Mack MJ, Holmes DR. Rational Dispersion for the Introduction of Transcatheter Valve Therapy. *JAMA*. 2011;306(19):2149-2150.
4. **Editorial:** Carroll JD, Shuren J, Syrek T Jensen, et al. Transcatheter Valve Therapy Registry Is A Model For Medical Device Innovation And Surveillance. *Health Affairs*, 34, no.2 (2015):328-334
5. **Editorial:** Sedrakyan A, Marinac-Dabic D, Holmes DR. *JAMA*. 2013 Jul 17;310(3):257-9
6. **03T:** Brennan JM, Holmes DR, Sherwood MW, et al. The association of transcatheter aortic valve replacement availability and hospital aortic valve replacement volume and mortality in the United States. *Ann Thorac Surg*. 2014 Dec;98(6):2016-22
7. **01T.** Carroll JD, Edwards FH, Marinac-Dabic D, et al. The STS-ACC Transcatheter Valve Therapy National Registry: A New Partnership and Infrastructure for the Introduction and Surveillance of Medical Devices and Therapies. *J Am Coll Cardiol*. 2013;62(11):1026-1034. doi:10.1016/j.jacc.2013.03.060.
8. **02T.** Mack MJ, Brennan JM, Brindis R. Outcomes Following Transcatheter Aortic Valve Replacement in the United States. *JAMA*. 2013 Nov;310(19):2069-2077. doi:10.1001/jama.2013.282043.
9. **No ID #.** Sedrakyan A(1), Marinac-Dabic D, Holmes DR. The international registry infrastructure for cardiovascular device evaluation and surveillance. *JAMA*. 2013 Jul 17;310(3):257-9
10. **44 (50T).** Thourani VH, Jensen HA, Babaliaros V, et al. Transapical and Transaortic Transcatheter Aortic Valve Replacement in the United States. *Ann Thorac Surg* 2015;100:1718–27
11. **74 (25T).** Suri RM, Gulack BC, Brennan JM, et al. Outcomes of Patients With Severe Chronic Lung Disease Who Are Undergoing Transcatheter Aortic Valve Replacement; The Annals of Thoracic Surgery, Available online 29 August 2015.
12. **107.** Holmes DR, Nishimura RA, Grover FL, et al. Annual Outcomes With Transcatheter Valve Therapy: From the STS/ACC TVT Registry. *J Am Coll Cardiol* 2015; ISSN 0735-1097.
13. **33.** Arnold SV, Spertus JA, Vemulapalli S, et al. Association of Patient-Reported Health Status With Long-Term Mortality After Transcatheter Aortic Valve Replacement Report From the STS/ACC TVT Registry. *Circ Cardiovasc Interv*. 2015;8

14. **109.** Sorajja P, Mack M, Vemulapalli S, et al. Initial Experience With Commercial Transcatheter Mitral Valve Repair in the United States. *JACC*. 2016; 67 (10)
15. **108.** Edwards FH, Cohen DJ, O'Brien SM, et al. Development and Validation of a Risk Prediction Model for In-Hospital Mortality After Transcatheter Aortic Valve Replacement. *JAMA Cardiol*. Published online March 09, 2016. doi:10.1001/jamacardio.2015.0326.
16. **72.** Arsalan M, Szerlip M, Vemulapalli S, et al. Should Transcatheter Aortic Valve Replacement Be Performed in Nonagenarians? Insights From the STS/ACC TVT Registry. *JACC*. 2016; 67 (10)
17. **27.** Alfredsson J, Stebbins A, Brennan JM, et al. Gait Speed Predicts 30-Day Mortality After Transcatheter Aortic Valve Replacement: Results From the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. *Circulation*. 2016;133
18. **37.** Baron SJ, Arnold SV, Herrmann HC, et al. Impact of Ejection Fraction and Aortic Valve Gradient on Outcomes of Transcatheter Aortic Valve Replacement. *J Am Coll Cardiol*. 2016;67(20):2349-2358. doi:10.1016/j.jacc.2016.03.514
19. **5.** O'Brien SM, Cohen DJ, Rumsfeld JS, et al. Variation in Hospital Risk-Adjusted Mortality Rates Following Transcatheter Aortic Valve Replacement in the United States: A Report from the STS/ACC TVT Registry. *Circ Cardiovasc Qual Outcomes*. 2016;9:560-565
20. Fadahunsi , OA, et al. Incidence, Predictors, and Outcomes of Permanent Pacemaker Implantation Following Transcatheter Aortic Valve Replacement: Analysis from STS/ACC TVT Registry, *JACC: Cardiovascular Interventions*, November 14, 2016, 9 (21) 2189-2199.
21. Chandrasekhar, J, Dangas, G, Yu, J, et al.; Sex-Based Differences in Outcomes With Transcatheter Aortic Valve Therapy; *JACC*; 12/2016;Vol 68 No. 25; Pages 2733-44
22. Arnold, SV, Spertus, JA, Vemulapalli, S, et al.; Quality-of-Life Outcomes After Transcatheter Aortic Valve Replacement in an Unselected Population: A Report from the STS/ACC TVT Registry; *JAMA Cardiol*. Published online February 01, 2017. doi:10.1001/jamacardio.2016.5302

## IN PRESS

1. **34.** Hira, R. Trends, Predictors and Adverse Outcomes of Off-Label Use of Transcatheter Aortic Valve Replacement (TAVR): Insights from the NCDR® STS/ACC TVT Registry.
2. **174.** Abramowitz. Outcomes of Transcatheter Aortic Valve Replacement in Patients with Diabetes Mellitus
3. **106.** Carroll, J. The Relationship Between Hospital Procedure Volume and Outcomes (Complications) of Transcatheter Aortic Valve replacement from the STS---ACC TVT Registry.

## **NCDR-wide Publications**

### **PUBLISHED**

1. **01-N.** Anderson HV, Weintraub WS, Radford MJ, et al. Standardized Cardiovascular Data for Clinical Research, Registries, and Patient Care A Report from the Data Standards Workgroup of the National Cardiovascular Research Infrastructure Project. A collaboration of the Duke Clinical Research Institute and the American College of Cardiology - National Cardiovascular Data Registry. J Am Coll Cardiol 2013;61:1835–46.
2. **02N-B.** Messenger JC, Ho KL, Young CH, et al. The National Cardiovascular Data Registry (NCDR) Data Quality Brief: The NCDR Data Quality Program in 2012. J Am Coll Cardiol. 2012 Oct 16; 60(16):1484-8.
3. **3-N.** Masoudi FM, Ponirakis A, Yeh RW, et al. Cardiovascular Care Facts: A Report from the NCDR - 2011. J Am Coll Cardiol. 2013 Nov 19/26; 62(21): 1931-1947.

### **IN PRESS**